{
  "name" : "zero.sci-hub.se_7031_8f99a76d9eb6a3cf3912202dbad496f1_10.1016@j.neubiorev.2018.07.011.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "The Role of Epigenetic Modifications in Neurodevelopmental Disorders: A Systematic Review",
    "authors" : [ "Lorenza Dall’Aglio", "Taulant Muka", "Charlotte A.M. Cecil", "Wichor M. Bramer", "Michael M.P.J. Verbiest", "Jana Nano", "Andrea Cortes Hidalgo", "Oscar H. Franco", "Henning Tiemeier", "Charlotte A. M. Cecil" ],
    "emails" : [ "h.tiemeier@erasmusmc.nl." ],
    "sections" : [ {
      "heading" : null,
      "text" : "Accepted Manuscript\nTitle: The Role of Epigenetic Modifications in Neurodevelopmental Disorders: A Systematic Review\nAuthors: Lorenza Dall’Aglio, Taulant Muka, Charlotte A.M. Cecil, Wichor M. Bramer, Michael M.P.J. Verbiest, Jana Nano, Andrea Cortes Hidalgo, Oscar H. Franco, Henning Tiemeier\nPII: S0149-7634(18)30210-0 DOI: https://doi.org/10.1016/j.neubiorev.2018.07.011 Reference: NBR 3179\nTo appear in: Received date: 27-3-2018 Revised date: 21-6-2018 Accepted date: 20-7-2018\nPlease cite this article as: Dall’Aglio L, Muka T, Cecil CAM, Bramer WM, Verbiest MMPJ, Nano J, Hidalgo AC, Franco OH, Tiemeier H, The Role of Epigenetic Modifications in Neurodevelopmental Disorders: A Systematic Review, Neuroscience and Biobehavioral Reviews (2018), https://doi.org/10.1016/j.neubiorev.2018.07.011 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.\nThe Role of Epigenetic Modifications in Neurodevelopmental Disorders: A\nSystematic Review\nLorenza Dall’Aglioa, Taulant Mukaa†, Charlotte A. M. Cecila,b,c†, Wichor M. Bramerd, Michael M.P.J. Verbieste, Jana Nanoa,f, Andrea Cortes Hidalgoa, Oscar H. Francoa, Henning Tiemeiera,b,g,*\na Department of Epidemiology, Erasmus University Medical Center-Sophia Children’s Hospital, PO Box 2040, 3000 CA Rotterdam, The Netherlands\nb Department of Child and Adolescent Psychiatry, Erasmus University Medical Center-Sophia Children’s Hospital, PO Box 2040, 3000 CA Rotterdam, The Netherlands\nc Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King’s College\nLondon, 10 Cutcombe Road, SE5 9RJ London, UK\nd Medical Library, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands\ne Department of Internal Medicine, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands\nf Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA\ng Department of Social and Behavioral Science, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA\n†Co-second authors\n*Corresponding author at: Department of Epidemiology, Erasmus University Medical Center-Sophia Children’s Hospital, PO Box 2040, 3000 CA, NA-2814, Rotterdam, The Netherlands. Email:h.tiemeier@erasmusmc.nl. Fax number: (+31) 107-044-657\nAC CE\nP ED\nM AN\nUS CR\nIP T\n2\nHighlights\n Epigenetic modifications play a role in neurodevelopment.\n Few epigenetic markers have been repeatedly identified in relation to ASD or ADHD.\n Suboptimal designs and heterogeneity hamper the interpretation of findings.\n Large hypothesis-free studies can provide insight into the epigenetics of ASD/ADHD.\nABSTRACT\nEpigenetic processes have been suggested as key mechanisms in the etiology of neurodevelopmental disorders. This systematic review summarizes the current evidence for an association between epigenetics and Autism Spectrum Disorder (ASD) and Attention/Deficit-Hyperactivity Disorder (ADHD). Six databases were searched until the 24th of October 2017. Of the 2169 retrieved articles, 29 met our inclusion criteria. While generally associations between epigenetics and neurodevelopmental disorders were reported, only a few findings were consistent across independent analyses. Differential epigenetic markers were repeatedly identified in OR2L13, C11orf21/TSPAN32, PRRT1 and H3K27 for autism, and in VIPR2 for ADHD. Overall, evidence of an association between epigenetic modifications and ASD or ADHD should be considered preliminary and based on studies suffering from numerous caveats. We highlight the need for carefully designed investigations and for greater homogeneity and provide specific recommendations for future research. Despite our current limited understanding, the suggestive findings and the rapid advances in the field hold the promise of a forthcoming elucidation of the role of epigenetic modifications in neurodevelopmental disorders.\nKey Words: ASD; ADHD; DNA methylation; histone modifications; epigenetics.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n3"
    }, {
      "heading" : "1. INTRODUCTION",
      "text" : "Neurodevelopmental disorders are psychiatric conditions arising in early life featuring abnormalities in the central nervous system development. These can lead to emotional and behavioral problems and impairments in psychological, social, academic and occupational functioning (American Psychiatric Association, 2013). Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) are among the most common and well-known neurodevelopmental conditions, afflicting about 1% and 5% of children, respectively (American Psychiatric Association, 2013). A rise in the prevalence rates of these conditions has recently been reported (American Psychiatric Association, 2013; Boyle et al., 2011), highlighting the need for careful explorations of pathways to disorder etiology; although higher rates might result from confounding factors such as increased disorder awareness and methodological issues (American Psychiatric Association, 2013; Polanczyk et al., 2014).\nASD is characterized by restricted and repetitive behaviors and impairments in social interaction\nand communication. Autism is currently conceptualized as a spectrum of disorders capturing the commonalities across previously identified subtypes (e.g. Asperger’s Disorder, Autistic Disorder) while allowing for heterogeneity within this condition (American Psychiatric Association, 2013). For instance, individuals requiring very substantial support as well as highly functioning persons can meet the criteria for this disorder. ADHD is defined by hyperactivity, impulsivity, inattention and difficulties in organization atypical for the age of the child. Individuals suffering from ADHD can exhibit clinical hyperactivity/impulsivity and inattention (combined presentation) or the predominance of either of these symptoms (predominantly inattentive presentation, predominantly hyperactive/impulsive presentation) (American Psychiatric Association, 2013).\nBoth neurodevelopmental disorders tend to persist into adulthood and can often co-occur, with the\nmanifestation of ADHD symptoms in 30% to 50% of autistic patients (Leyfer et al., 2006; Lichtenstein et\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n4\nal., 2010; Taurines et al., 2012). The etiology of neurodevelopmental disorders is complex and involves multiple determinants. A substantial genetic component is present in both psychiatric conditions (American Psychiatric Association, 2013; Elia et al., 2012; Faraone et al., 2005; Loke et al., 2015; Tordjman et al., 2014). Furthermore, environmental factors, such as prenatal maternal stress and exposure to toxins, play a considerable role (American Psychiatric Association, 2013; Kubota and Mochizuki, 2016; Loke et al., 2015; Schuch et al., 2015); however, the processes through which the environment, by interacting with genetic susceptibilities, leads to the development of neurodevelopmental disorders are yet to be elucidated (Keil and Lein, 2016).\nEpigenetic modifications have been suggested as the mechanisms responsible for the biological\nencoding of environmental influences, representing the meeting point of genes and environment (Feil and Fraga, 2012; Keil and Lein, 2016; LaSalle, 2013; Latham et al., 2012). Epigenetic processes can regulate gene expression, without affecting underlying DNA sequences (Feil and Fraga, 2012). While there is growing evidence that epigenetic processes are sensitive to numerous environmental exposures (e.g. nutritional factors) (Feil and Fraga, 2012), the effect of genetic variation on epigenetic markers has also been documented (Kilpinen and Dermitzakis, 2012). Regardless of their determinant, epigenetic modifications are considered relevant factors in the etiology of complex disorders such as ASD and ADHD, which could account for the unexplained variance of disorder occurrence.\nThe most studied epigenetic changes are DNA methylation and histone modifications. The former\noccurs when a methyl group is added to specific DNA base pairs, primarily in the context of cytosineguanine dinucleotides (CpGs). Methyl groups regulate gene expression determining activation or inhibition of activity, according to the methylated location (e.g. gene body, CpG island) (Moore et al., 2013) and to the degree of DNA methylation, typically expressed as hypomethylation (i.e. lower levels of DNA methylation) or hypermethylation (i.e. higher levels of DNA methylation). The three most common approaches to profile DNA methylation patterns are global, epigenome-wide and candidate gene DNA methylation analyses. Global DNA methylation provides an average estimate of DNA methylation levels\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n5\nin the analyzed tissue sample by quantifying the methylcytosine (5-mC) present in the genome (Non and Thayer, 2015). In contrast, candidate gene DNA methylation studies and Epigenome-Wide Association Studies (EWAS) examine DNA methylation at specific CpG sites or regions and are thus defined as sitespecific studies. More precisely, EWAS are typically hypothesis-free and screen up to hundreds of thousands of loci across the genome to identify CpGs or regions associated with the disorder of interest. In contrast, candidate gene DNA methylation analyses target loci in one or a limited number of specific genes, based on a priori hypotheses.\nPost-translational histone modifications are a group of epigenetic alterations (e.g. lysine\nmethylation and histone acetylation) which remodel chromatin structure and which are associated with variations in DNA expression (Bannister and Kouzarides, 2011). Histone acetylation is consistently related to transcriptional activation (Kouzarides, 2007), whereas the transcriptional consequences of methylation are determined by the position of such modification. For instance, while methylation in histone three lysine four (H3K4) is involved in activation of DNA expression, methylation in histone three lysine 27 (H3K27) is implicated in repression.\nMultiple publications have provided evidence of differential DNA methylation between cases and\ncontrols in ASD and ADHD (Loke et al., 2015; Walton et al., 2017) and of histone modifications in patients with ASD only (Sun et al., 2016). However, a comprehensive assessment of the epigenetic modifications present in both neurodevelopmental disorders is currently lacking. Therefore, the aim of this systematic review is to identify, integrate and discuss all available evidence on the association of DNA methylation and histone modifications with ASD and ADHD."
    }, {
      "heading" : "2. MATERIALS AND METHODS",
      "text" : ""
    }, {
      "heading" : "2.1 Literature Search",
      "text" : "In order to conduct this review, we followed a predefined protocol adhering to the PRISMA and MOOSE guidelines (Appendices 1 and 2). The search of six bibliographic databases (Embase.com, Web-of-\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n6\nScience, Medline (Ovid), Cochrane Central, PsycINFO Ovid and Google Scholar) was performed on January 12th 2017 and updated on October 24th 2017 (last data search), in collaboration with a medical information specialist. The searched terms referred to both exposure (e.g. epigenetics, histone, DNA methylation, CpG) and outcomes (e.g. neurodevelopmental disorders, ASD, ADHD). We limited the search to studies on humans, but no language, tissue type (in vivo or post-mortem) or publication date restrictions were applied. The complete search strategies can be found in Appendix 3. To retrieve further relevant publications, we consulted experts and examined literature reviews on the topic."
    }, {
      "heading" : "2.2 Study Selection and Inclusion Criteria",
      "text" : "Studies were included if they described the association between epigenetic marks (DNA methylation or histone modifications) and ASD or ADHD. The excluded studies (i) referred to epigenetic marks different from histone modifications and DNA methylation; (ii) examined neurodevelopmental disorders other than ASD and ADHD, such as Down Syndrome, Fetal Alcohol Spectrum Disorder and Intellectual Disability; (iii) were not empirical studies; (iv) did not compare cases to controls. Psychiatric disorders other than ASD and ADHD were excluded in order to limit the scope of our systematic review to two of the most common and comorbid forms of neurodevelopmental conditions. Additionally, the traits (e.g. high negative affect) and etiological factors shared by ASD and ADHD (Visser et al., 2016) point to the possibility of similar biological profiles. Other disorders of neurodevelopmental etiology, such as schizophrenia, have been reviewed elsewhere (Fullard et al., 2016; Homberg et al., 2016; van Bokhoven, 2011). Two independent reviewers selected the publications meeting the inclusion criteria by examining titles and abstracts. In case of disagreement a senior researcher was available, but all divergences regarding the chosen articles were discussed and solved between the two reviewers. Full texts of the studies of interest were retrieved and a further selection was performed according to the inclusion and exclusion criteria.\n2.3 Data Extraction\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n7\nThe relevant information from the studies was collected in predesigned data forms, which varied according to the type of approach (global, candidate gene, epigenome-wide DNA methylation and histone modifications) and which were subdivided by tissue examined (brain tissue or peripheral – other tissues such as blood and saliva-). These data forms included the neurodevelopmental disorder outcome (ASD or ADHD), sample size (cases/controls), sample characteristics (population, age range or mean age and sex), tissue type, the methodology for epigenetic marks assessment (type of statistical analysis and platform), the presence of validation or replication, adjustments or matching and a summary of the findings with reported statistics (e.g. p-values) (Tables 1-6). Of note, validation refers to the verification of findings in the same sample with the use of a different methodology. Replication instead entails testing a new group of participants.\nWhen the required information was not presented in the included articles, we contacted\ncorrespondence authors. If there was no response, we classified the missing information as “not available” (NA). Data extraction was performed by one author, who was assisted by a research analyst in the identification of platforms used."
    }, {
      "heading" : "2.4 Assessing the Risk of Bias",
      "text" : "Although PRISMA and MOOSE guidelines require quality assessment of the included studies, we decided not to perform a formal evaluation due to the lack of specific guidelines for epigenetic studies (e.g. required sample size according to approach, platform coverage, performance of validation)."
    }, {
      "heading" : "2.5 Outcome Assessment and Statistical Methods",
      "text" : "For each study, we defined whether an association was present and, when applicable, effect sizes were reported. We sought to pool the results using a random effects meta-analysis model. However, due to high heterogeneity in the input parameters, assumptions and study design, it was not feasible to perform quantitative pooling of the existing data.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n8"
    }, {
      "heading" : "3. RESULTS",
      "text" : "As shown in Figure 1, through a literature search and other sources, we identified 2169 potentially relevant articles. Of these, 29 met the eligibility criteria and were thus included in this review. Reasons for exclusion of individual articles can be disclosed upon request. In the following section, we provide a summary of all included studies, followed by a review of their findings. Results are presented for each neurodevelopmental disorder separately and further subdivided according to the approach employed (global DNA methylation, candidate gene DNA methylation studies, EWAS and histone modifications) and tissue examined (brain, peripheral)."
    }, {
      "heading" : "3.1 Summary of included studies",
      "text" : "Overall, ASD was examined in 24 publications (global DNA methylation, candidate genes, EWAS and histone modifications) and ADHD in five (candidate genes and EWAS). No study focused on epigenetic marks in both disorders.\nCross-sectional designs comparing cases and controls were commonly used (n=24). A few\npublications examined participants prospectively in nested case-control studies (Schroeder et al., 2016; Van Mil et al., 2014; Walton et al., 2017) or compared monozygotic twins discordant for the disorder of interest (Nguyen et al., 2010; Wong et al., 2014). Of the included studies, 11 sampled individuals in the USA, three in China and two in the UK. The remaining studies were from Spain, Croatia, Italy, The Netherlands, comprised multiple samples of participants from mixed countries, or, did not specify the sample nationality. The selected publications mainly included individuals with mixed age at epigenetic assessment (n=15). Other articles sampled the tissues of the participants during the neonatal period (n=3), childhood (n=5) or adolescence (n=1). Of these, Walton et al. (2017) assessed epigenetic marks at multiple time points during the neonatal period and childhood. No study targeted an adult population only, while six publications did not disclose the patients’ age. Regarding tissue sampling, 17 studies analyzed peripheral tissue (blood, lymphoblastoid cell lines, leucocytes, cord blood, buccal epithelium, placenta, and saliva) while12 used post-mortem brain tissue (cerebellum, cortices - temporal, occipital, AC CE PT ED\nM AN\nUS CR\nIP T\n9\n(pre)frontal cortex -, pons, Brodmann’s areas and fusiform gyrus). The most commonly examined tissues were blood and cerebellum.\nThe majority of the publications used a candidate gene (n=14) or EWAS (n=14) approach to test\nthe presence of differential epigenetic marks. Few studies only quantified global DNA methylation (n=5) or histone modifications (n=2). Five publications employed multiple approaches to epigenetic analysis as shown in Supplementary Table S1. Different methods were used to assess global DNA methylation status (e.g. HPLC tandem mass spectrometry (LC-MS/MS)). The included site-specific methylation studies mainly examined differentially methylated positions (DMP) or differentially methylated regions (DMR). Most of the candidate gene DNA methylation studies used bisulfite pyrosequencing, a quantitative approach with high reproducibility, but with relatively short length of reads (Non and Thayer, 2015). The most commonly used platform in epigenome-wide analyses was the Illumina Infinium HumanMethylation450K BeadChip (Infinium (HM)450K array)), which allows for the screening of over 450’000 CpG sites with high quantitative accuracy (Non and Thayer, 2015). The platform covers approximately 2% of all human CpG sites and underrepresents several genomic components such as enhancer regions (Barker et al., 2017). Of the 14 EWAS, four included an independent sample to confirm the findings from the discovery analysis (Aldinger et al., 2013; Homs et al., 2016; Ladd-Acosta et al., 2014; Wilmot et al., 2016), while ten validated their results using an independent approach in the same cluster of participants (e.g. Berko et al., 2014; Nardone et al., 2017). Of the candidate gene DNA methylation studies, only one study conducted a validation analysis (Jiang et al., 2004). Adjustments or matching for age or sex were generally performed. A few studies controlled for additional covariates such as batch effects, cell heterogeneity, and post-mortem brain interval. More information on the characteristics of the included publications can be found in Tables 1-6."
    }, {
      "heading" : "3.2 Autism Spectrum Disorder",
      "text" : "3.2.1 Global DNA Methylation AC CE PT ED M AN US CR IP T\n10\nGlobal DNA methylation status of autistic patients and controls was compared in five publications, two focusing on brain and three on peripheral tissue. Characteristics and findings of global DNA methylation studies investigating ASD are available in Table 1.\nBrain Tissue: No consistent associations between global DNA methylation and autism were\nidentified by two independent studies in brain tissue. James et al. (2013) detected statistically significant DNA hypermethylation through Tandem Mass Spectrometry (LC/MS/MS) in the cerebellum of 13 autistic subjects when compared to 13 controls of mixed age (M ± SD = 5.9±1.2 in cases, 4.7±1.1 in controls). Contrasting results were reported by Mitchell et al. (2012), who did not find proof for significant global DNA methylation differences in LINE-1 elements in Brodmann’s area 19 of 12 cases and 12 controls of mixed age.\nPeripheral Tissue: No consistent associations of global DNA methylation with autism were\nreported by three independent studies in peripheral tissue. Two articles did not find evidence for differences in whole blood, placenta and cord blood of children up to 15 years by employing MethylCsequencing and Luminometric Methylation Assay (LUMA) (Schroeder et al., 2016; Wong et al., 2014). Tsang et al. (2016), who used restriction enzymes for their research, found DNA hypermethylation in the leucocytes of 280 autistic five-year-old children (∆β = 54.35±21.37). 3.2.2 Epigenome-Wide DNA Methylation The association between genome-wide DNA methylation and ASD was examined in 12 studies, five focusing on brain and seven on peripheral tissue. Characteristics and findings of the included epigenomewide analyses investigating ASD can be found in Table 2.\nBrain Tissue: Associations between differential DNA methylation and autism in a genomic area\nencompassing Chromosome 11 open reading frame 21 (C11orf21) and Tetraspanin 32 (TSPAN32) were found by three independent analyses (Ladd-Acosta et al., 2014; Nardone et al., 2014). Ladd-Acosta et al. (2014) sampled the cerebellum and temporal and prefrontal cortices of 20 cases and 21 controls in a genome-wide significant regional change analysis. They reported DNA hypomethylation of\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n11\nC11orf21/TSPAN32 (∆M = -6.6%) in the temporal cortex and replicated their findings in different brain regions (cerebellum and pre-frontal cortex) within the same genomic region. Consistent with these results, Nardone et al. (2014) showed differential DNA methylation of C11orf21/TSPAN32 in Brodmann’s area 10 between 12 cases and 12 controls of mixed age and validated this finding (∆β = 0.39 to -4.93). Associations in Proline Rich Transmembrane Protein 1 (PRRT1) were consistently identified by three analyses. Ladd-Acosta et al. (2014) reported DNA hypomethylation of regions in PRRT1, both in the discovery (∆M = -7.8%) and replication samples. Nardone et al. (2014) additionally found differential DNA methylation in CpGs in PRRT1.\nOther findings of differential DNA methylation were identified in sites/regions in, or near,\nSNORD family genes in frontal and temporal cortices and cerebellum (Feinberg et al., 2015), ZFP57 (∆M = 13.9%), SDHAP3 (∆M = 15.8%) in prefrontal and temporal cortices and cerebellum (Ladd-Acosta et al., 2014), HDAC4, C1qA, IRF8 and CTSZ in Brodmann’s areas 10 and 24 (Nardone et al., 2014), GABBR1, ABAT, Mir124-1, Mir124-2, FAM124B, InNEAT1 in prefrontal cortex, Brodmann’s areas 10 and 24 (Nardone et al., 2017). Of these, C1qA (∆β = -3.45), IRF8 (∆β = -3.42) and CTSZ (∆β = -2.13 to - 3.39) (Nardone et al., 2014), GABBR1 and Mir124-2, FAM124B and InNEAT1 (Nardone et al., 2017) were validated. An epigenome-wide analysis of Brodmann’s area 19, occipital and cerebellar cortices found no evidence for differences in DNA methylation between cases and controls of mixed age (Ginsberg et al., 2012).\nPeripheral tissue: Associations between differential DNA methylation and autism in Olfactory\nReceptor family 2 subfamily L member 13 (OR2L13) – a gene involved in the neuronal response to odorants - were found by two independent studies sampling peripheral tissue (Berko et al., 2014; Wong et al., 2014). Berko et al. (2014) reported differential DNA methylation between 47 cases and 48 controls in buccal tissue in a cross-sectional study comprised of participants of mixed age (β = -8.0%). Wong et al. (2014), in a longitudinal analysis from birth till age 15, found differential DNA methylation of OR2L13 between 66 cases and 44 controls in whole blood (∆β = 0.18); this finding was validated. Differentially\nAC CE\nPT ED\nM A\nUS CR\nIP T\n12\nmethylated markers in ENO2 – a gene coding for an isoenzyme present in mature neurons - were partially identified by two independent analyses carried out by Wang et al. (2014). In their discovery cohort, they showed DNA methylation differences in 228 gene promoters and 247 CpG islands, including the ENO2 promoter region, between 5 autistic children and 5 controls ranging from three to twelve years in venous blood. In their replication sample, they confirmed hypermethylation in correspondence to the ENO2 promoter in 15% of a sample comprising 131 pairs of cases and controls (M = 39.1% in cases, M = 18.81% in controls).\nOther publications reported the presence of contrasting epigenetic patterns between cases and controls in or near the following genes: TAC1, PTCD2, HOXA11, TCN1, ETNK2, SPAG7, FLJ44881 (|∆β| > 0.15) (Aldinger et al., 2013), BCL2 (M = 25% in cases, M = 9.5% in controls) and RORA in lymphoblastoid cell lines (Nguyen et al., 2010), DLL1 and LOC15444 in placenta (Schroeder et al., 2016), PIK3C3 (∆β = - 0.04), NFYC, C14orf152 (∆β = -0.16) and MGC3207 (∆β = -0.24) in blood (Wong et al., 2014), PAX8 (β = -7.5%), GPC1 (β = -8.6%), ADRA2C (β = -11.9%), FAM134B (β = -7.8%), CREB5 (β = 7.6%), NOS1 (β = 8.6%), MAPK8IP3 (β = 9%), HOOK2 (β = -7.9%), NRG2 (β = 7.6%), KCNQ5 (β = 7.7%), ZG16B (β = 10.1%), LOC643802 (β = -8.9%) in buccal tissue (Berko et al., 2014). Of these, BCL2, RORA (Nguyen et al., 2010), DLL1 (Schroeder et al., 2016), TAC1(Aldinger et al., 2013), and MGC3207 (r = 0.91) (Wong et al., 2014) were validated. Only one study did not find evidence for differential DNA methylation patterns between cases and controls of mixed age in blood tissue (Homs et al., 2016). However, the authors did report epigenetic differences in 700 CpG sites when each individual patient was compared to ten controls; 17 of these sites were replicated.\n3.2.3 Candidate Gene DNA Methylation The relation between DNA methylation and ASD was examined in 11 candidate gene DNA methylation studies collectively spanning 16 genes, 2 of which (MeCP2 and UBE3A) were selected by multiple\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n13\nauthors. Seven publications investigated brain tissue while four examined peripheral tissue. Characteristics and findings of all candidate gene DNA methylation studies examining ASD can be found in Table 3.\nBrain Tissue: Associations in MeCP2 – a gene coding for a protein with a methyl-CpG binding\ndomain ([dataset] Geer et al., 2010) - were examined by three studies in mixed-age samples but could not be replicated. Nagarajan et al. (2006) reported DNA hypermethylation in autistic patients in MeCP2 region I in Brodmann’s area 9 and in fusiform gyrus tissue. In a subsequent study, the same author showed no proof for statistically significant differences in region II of MeCP2 in Brodmann’s area 9 (Nagarajan et al., 2008). Ginsberg et al. (2012) reported no evidence for DNA methylation differences in MeCP2 in Brodmann’s area 19, occipital cortex and cerebellar hemispheric cortex, but they did not specify which genetic region was analyzed.\nOther studies found differential DNA methylation distribution in autistic subjects of mixed age in\nthe RELN promoter region within Brodmann’s areas 41/42 and 22 (M ± SD = 29.55 ± 13.09 in cases, 5.70 ± 2.90 in controls) (Lintas et al., 2016) and higher DNA methylation in the EN-2 gene within the cerebellum (M ± SD = 23±4% to 38±7% in cases, 10±2% to 15±5% in controls) (James et al., 2013). A replication was not attempted. No proof for significant differences was found in correspondence to RORA, BCL2 and OXTR in Brodmann’s area 19 and cerebellar hemispheric cortices (Ginsberg et al., 2012), UBE3A in Brodmann’s area 19, cortices and cerebellum (Ginsberg et al., 2012; Jiang et al., 2004), SNRPN in cerebellum and cerebral cortex (Jiang et al., 2004), and OCA2 in Brodmann’s area 19 (Mitchell et al., 2012).\nPeripheral Tissue: There was no attempt to replicate findings in candidate gene DNA methylation\nstudies comparing autistic patients and controls in peripheral tissue. Hranilovic et al. (2016) found higher DNA methylation in autistic subjects of mixed age in a region of HTR2A – a gene encoding a receptor for serotonin ([dataset] Geer et al., 2010) - in the leukocytes of AG genotype carriers only. No evidence for significant differences was found in correspondence to FOXK1 in blood (Atsem et al., 2016), PEG1 and\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n14\nCOPG2 in leucocytes (Bonora et al., 2002) and PEG13, KCNK9 and TRAPPC9 in peripheral blood (Delgado et al., 2014). 3.2.4 Histone Modifications\nThe association between histone modifications and ASD was assessed by two studies in the brain tissue of mixed age populations (James et al., 2013; Sun et al., 2016). They analyzed different histone modifications (methylation and acetylation) on H3K27. James et al. (2013) reported lower trimethylation levels of H3K27 in the cerebellum of 11 autistic patients when compared to 11 controls. Consistently, Sun et al. (2016) found differential acetylation of H3K27 between 45 cases and 49 controls in the cerebellum, prefrontal and temporal cortices. No evidence for H3K4 to be differentially trymethylated was found in the cerebella of cases and controls (James et al., 2013). Further information regarding the studies examining histone modifications can be found in Table 4."
    }, {
      "heading" : "3.3 Attention-Deficit/Hyperactivity Disorder",
      "text" : "The relation between epigenetic modifications and ADHD was investigated with the use of epigenomewide and candidate gene approaches only. 3.3.1 Epigenome-Wide DNA Methylation\nThe relation between ADHD and epigenome-wide DNA methylation was examined by two studies (Walton et al., 2017; Wilmot et al., 2016) and in peripheral tissue only. Differential DNA methylation in Vasoactive Intestinal Peptide Receptor 2 (VIPR2) was found in two independent analyses carried out by Wilmot et al. (2016). In a discovery sample comprising 43 children with ADHD and 42 controls ranging from seven to 12 years, they identified differential DNA methylation in 95 genes, including VIPR2 (β = - 0.059). Subsequently, in a replication sample of 10 pairs of cases and controls, they confirmed DNA hypomethylation in one of the previously identified CpG sites in VIPR2 (cg13444538) (β = -0.096).\nAnother study by Walton et al. (2017), using prospective data, reported contrasting epigenetic\npatterns in cord blood between 40 children with a chronic high vs 777 with a low trajectory of ADHD, in\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n15\nthe proximity of SKI (β = -0.2), EPX (β = -0.18), PEX2 (β = 0.17), ST3GAL3 (β = -0.17), FBXW5 (β = 0.17), ELF3 (β = 0.17), ZNF544 (β = 0.17). These epigenetic differences were no longer observable at age 7 in whole blood. Further information on the publications investigating epigenome-wide DNA methylation in ADHD can be found in Table 5.\n3.3.2 Candidate Gene DNA Methylation The relation between candidate gene DNA methylation patterns and ADHD was analyzed in three studies (Adriani et al., 2017; Van Mil et al., 2014; Xu et al., 2015) in peripheral tissues only. Associations between differential DNA methylation and ADHD in SLC6A3/DAT1 – a gene encoding a dopamine transporter ([dataset] Geer et al., 2010) - were analyzed by two independent studies. Adriani et al. (2017) showed DNA hypomethylation of the SLC6A3 gene in 30 cases compared to 15 controls ranging from six to 12 years in blood and buccal tissues. In contrast, Xu et al. (2015) did not observe differential DNA methylation patterns in DAT1 between 50 children suffering from ADHD and 50 controls ranging from four to 12 years.\nAssociations between differential DNA methylation and ADHD in DRD4 – a gene encoding a\ndopamine receptor ([dataset] Geer et al., 2010) - were found by two independent studies; however, the direction of the effect was inconsistent (Van Mil et al., 2014; Xu et al., 2015). Van Mil et al. (2014) reported DNA hypomethylation in DRD4 in the cord blood of children with ADHD (β = -0.52). Xu et al. (2015) additionally showed DNA hypermethylation in individuals with ADHD in correspondence to DRD4.\nVan Mil et al. (2014) also found hypomethylation of 5-HTT in cord blood (β = -0.22). No\nevidence for significantly different epigenetic marks was identified in CpGs in, or near, IGF2, H19, KCNQ1OT1, MTHFR and NR3C1 (Van Mil et al., 2014). More information on the studies examining candidate gene DNA methylation in ADHD can be found in Table 6.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n16"
    }, {
      "heading" : "4. DISCUSSION",
      "text" : "The present work aimed to provide a comprehensive evaluation of the current evidence for the relation of differential epigenetic markers with ASD and ADHD. To our knowledge, this is the first systematic review examining epigenetic modifications in each neurodevelopmental disorder.\nOf the 29 included publications, the majority focused on DNA methylation, examined autism and\nselected a cross-sectional design. Studies used different tissues and analytical approaches. These results provide preliminary support for an association between epigenetic alterations and neurodevelopmental disorders. Yet, the mixed findings, the small-sized samples, and the low comparability of publications prohibit definite conclusions."
    }, {
      "heading" : "4.1 Summary of key Findings",
      "text" : "Of the small set of studies investigating global DNA methylation in relation to autism, some identified hypermethylation in cases while others found no evidence for differences between groups. Similarly, mixed results have been reported in the global DNA methylation patterns of individuals affected by neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and other chronic diseases (Braun et al., 2016; Muka et al., 2016a; Muka et al., 2016b; Wen et al., 2016). Inconsistencies might stem from heterogeneity in (i) the tissues selected (e.g. blood vs brain tissue), (ii) the analytical and statistical methods used (e.g. differences in DNA methylation assessment methods, analytic routines and significance thresholds) and, (iii) the sample characteristics (e.g. age differences). Generally, hypothesisfree approaches (EWAS) did not yield consistent results although often the same array was employed. Nevertheless, the identification of differential DNA methylation in the proximity of three genes – PRRT1, C11orf21/TSPAN32, and OR2L13 - in multiple independent analyses, is a promising preliminary finding. Mutations in the gene family of PRRT1 are involved in neurological disorders such as familial infantile seizure (Ladd-Acosta et al., 2014). A similar role in normal/neurological phenotypes was described for the mice homolog prrt1, which is also implicated in central nervous system functioning ([dataset] Smith et al., 2018). The genomic area encompassing C11orf21 and TSPAN32 could constitute a bidirectional promoter, AC CE PT ED M AN\nUS CR\nIP T\n17\nhence a DNA region in which transcriptional processes of two genes are commenced in opposite orientations from a putative promoter. Given the important role of bidirectional promoters in gene regulation and in the production of both coding and non-coding RNA (Wei et al., 2011), we speculate that epigenetic alterations within C11orf21/TSPAN32 might lead to pervasive effects in transcriptional regulation at a genome-wide level. The function of C11orf21 is yet to be elucidated, although one study suggested its role in cytoplasmic localization (Zhu et al., 2000). In contrast, more information is available for TSPAN32, which is located within the tumor-suppressor gene region encompassing chromosome 11p15.5 ([dataset] Geer et al., 2010). DNA methylation alterations in TSPAN32 were found to relate with Beckwith-Wiedemann syndrome ([dataset] Geer et al., 2010), a disease characterized by genetic and epigenetic dysregulation ([dataset] Shuman et al., 2016; Weksberg, 2010). The increased incidence of autism among individuals suffering from Beckwith-Wiedemann syndrome ([dataset] Shuman et al., 2016; Betancur, 2011) suggests that TSPAN32 DNA methylation status might play a role in both disorders. Moreover, mutations in another member of the tetraspanin family, TSPAN8, were described in other psychiatric conditions, namely in schizophrenia and bipolar disorder (Scholz et al., 2010). OR2L13 is responsible for the initialization of the neuronal response to odorants (Berko et al., 2014). Mice studies have also observed involvement in olfactory receptor activity in the homologs of OR2L13, olfr166 and olfr168 ([dataset] Smith et al., 2018). Olfactory dysfunctions have been reported in autistic patients and were found to correlate with the social impairment component of the disorder (Bennetto et al., 2007; Hilton et al., 2010). DNA methylation differences in OR2L13 between cases and controls were not found in monozygotic twins discordant for the disorder (Wong et al., 2014), indicating the possibility of an influence of genetic variants on these epigenetic markers. As evident through a mQTL database search (Gaunt et al., 2016), the CpG of interest (cg20507276) was indeed related to numerous single nucleotide polymorphisms. Yet results should be interpreted with caution because of numerous caveats in the literature, such as the very small sample size employed and the use of platforms with lower CpG coverage (Infinium 27k array). A number of shared biological pathways of relevance to neurodevelopment were AC CE PT ED M AN US CR IP T\n18\nreported by independent EWAS, including synaptic and neuronal processes (Nardone et al., 2017; Nguyen et al., 2010), immune response processes (Nardone et al., 2017; Nardone et al., 2014; Nguyen et al., 2010), brain development (Nguyen et al., 2010) and cellular differentiation (Table 2). Candidate gene studies of autism identified DNA methylation differences in multiple genes; however, the absence of replication implies that the field lacks credible data to assess how DNA methylation of specific a priori genes associates with autism. Histone modifications (trimethylation and acetylation) in association with ASD were consistently found in H3K27 in the cerebellum and cortices of autistic patients. Yet, a role of these variations in autism can only be inferred very cautiously due to the high reversibility and complicated mechanisms that histone modifications entail.\nAssociations of epigenetic patterns with ADHD were explored in a few studies only, which\nfocused on site-specific DNA methylation. Overall, epigenome-wide approaches to DNA methylation analysis provided inconsistent findings. Nevertheless, VIPR2 was recognized as hypomethylated in two independent samples by Wilmot et al. (2016). Duplications and SNPs in VIPR2 seem to be implicated in schizophrenia and mood disorders, respectively. Vipr2 was also found to be involved in hypo-activity in mice models ([dataset] Smith et al., 2018). Based on this finding and on their research, Wilmot et al. (2016) speculated the possibility of a relation between human hyperactivity symptoms and decreased DNA methylation in VIPR2. Further investigations are needed. Interestingly, both VIPR2 (for ADHD) and OR2LI3 (for ASD) are involved in the signaling by G-protein-coupled-receptors (GPCR) pathway ([dataset] Weizmann Institute of Science, c2018), which includes genes responsive to stimuli external to the cell, including odors and neurotransmitters. This might indicate that epigenetic dysregulation of the signaling by GPCR pathway could be characteristic of both neurodevelopmental disorders; however, it should be noted that only two of the 2’601 genes included in this network were observed as differentially methylated. Further pathways involved in ADHD shared by non-replicated sites/regions include peroxisomal processes and transcriptional activity (Table 5) (Wilmot et al., 2016). Candidate gene DNA AC CE PT ED M AN\nUS CR\nIP T\n19\nmethylation studies of ADHD could not find consistent evidence of differential DNA methylation between cases and controls or did not attempt to replicate their results."
    }, {
      "heading" : "4.2 Current Challenges in the Field and Recommendations for Future Research",
      "text" : "When interpreting the reported findings, multiple methodological issues should be acknowledged. First, the selected DNA methylation assessment method (global, candidate gene and genome-wide DNA methylation analysis) might explain reported inconsistencies (e.g. direction of DNA methylation differences – hypo, hyper – and lack of converging findings in epigenome-wide and candidate gene studies). Global DNA methylation might not be a sufficiently fine-grained method since epigenetic modifications in psychiatric phenotypes are likely to be subtle and site-specific compared to disorders characterized by large-scale genomic instability. Although epigenome-wide and candidate gene approaches permit a more detailed assessment of DNA methylation, these two methods diverge on several aspects. With the setback of higher statistical burden and costs, epigenome-wide analysis permits a wider coverage of the genome and the discovery of differentially methylated genes, which could otherwise be disregarded. A hypothesis-free approach thus appears the most appropriate when knowledge on the epigenetics of the disorder is limited, as in ASD and ADHD. Yet, epigenome-wide studies require more stringent guidelines before we can successfully identify true and consistent effects (Heijmans and Mill, 2012). Overall, we are confident that once EWAS are more standardized and well-powered, it will be possible to meta-analyze findings and to detect consistent alterations in DNA methylation.\nSecond, the selection of statistical analyses likely influenced the detection of differentially\nmethylated patterns. The included studies mainly analyzed differentially methylated positions (site-by-site analysis) or regions (regional change analysis). The former consider the association of each differentially methylated site with the disorder of interest, while the latter provide a proportion of the methylated cytosines in a specific area of the gene (Mill and Heijmans, 2013). Currently, there is no consensus on the most appropriate statistical analysis for epigenetic studies. Combination of approaches would enable the\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n20\nidentification of single abnormally methylated CpGs (site-by-site analysis), as well as the clustering of correlated sites (regional analysis or other reduction-based strategies) which are likely to be functionally relevant. This was performed in few of the reviewed studies (Aldinger et al., 2013; Homs et al., 2016; Nardone et al., 2014), which exemplify the current developments in the field.\nMost of the selected publications measured differential DNA methylation patterns based on\nbisulfite-treated DNA, which involves the deamination of non-methylated cytosines to uracil while leaving unaltered the methylated cytosines. A major setback of bisulfite conversion is the inability to distinguish between 5-mC and 5-hydroxymethylcytosine (5-hmC), another form of epigenetic modification involving the oxidation of 5-methylcytosine (Huang et al., 2010). Profiling 5-hmC separately could be insightful for ASD and ADHD research, given its role in neurodevelopment and disease. For instance, together with TET proteins, 5-hydroxymethylcytosine is considered to be involved in the DNA demethylation of 5-mC occurring during epigenetic reprogramming in the developing germline or in the early embryonic phase (Hill et al., 2014). In line with this, developmental regulation of 5-hmC quantities, with an increase from early postnatal stage to adulthood, has been reported in mice brain tissue (Szulwach et al., 2011). Of the included studies, none distinguished 5-hmC from 5-mC, indicating that the reported findings might not accurately portray the DNA methylation patterns of the participants, especially in brain tissue where 5-hmC is enriched. The implementation of methods enabling the distinction between 5-mC and 5-hmC, such as oxidative bisulfite sequencing (Booth et al., 2012), could enable advancements in the understanding of the epigenetic processes involved in neurodevelopmental and related disorders.\nA key issue in epigenetic research and especially in the included publications is the use of small\nsample sizes. Although there are no general guidelines, Tsai and Bell (2015) estimated the minimum number of participants necessary to reach 80% power according to multiple factors such as the mean DNA methylation difference present between affected and unaffected individuals. In particular, they reported that EWAS should include at least 54 case-control pairs to have adequate power to detect a 15% mean DNA methylation difference at a genome-wide significance. With the exception of a couple of studies\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n21\n(Homs et al., 2016; Wang et al., 2014), none of the included publications met this criterion indicating that most epigenome-wide analyses likely did not have the power to detect true DNA methylation differences. It is thus of utmost importance to consider the gathered results as preliminary and to interpret them with caution. It should also be noted that since mean DNA methylation differences between cases and controls at single CpG sites are likely to be small in effect size, much larger samples should be employed.\nThe included publications were mostly comparing cases and controls cross-sectionally, meaning\nthat causal inferences could not be drawn due to the presence of the disorder during assessment. Contrarily, a prospective design, which allows for measuring epigenetic patterns pre-symptom onset, could elucidate the direction of the epigenetics-disorder relation. Monozygotic-twin discordant studies are another substantial resource as they control for the influence of genetic variants and display DNA methylation changes arising from discordant environmental exposures. The results stemming from both monozygotic-twin discordant and longitudinal designs should be integrated to identify the direction of the epigenetics – disorder relation (longitudinal design), as well as the influence of genetic variants on epigenetic markers (twin-discordant study). The use of repeated measurements in longitudinal studies would provide further insight, as exemplified by Walton et al. (2017), whose results varied with age of the children.\nRegardless of the design, findings can be hampered by confounding variables influencing the\nassociation between DNA methylation and symptomatology of the disorder and causing inflated and inaccurate results. Although the majority of the included publications corrected for potential third variables, among which sex and age were the most common, adjustments for technical covariates such as batch effects and cell type were performed by a few studies only (e.g. Berko et al., 2014; Nardone et al., 2017).\nThe included publications mainly examined brain and blood. Because of epigenetic tissue\nspecificity (i.e. each tissue has its specific epigenetic patterns), peripheral tissues may not be appropriate surrogates to estimate alterations in the brain of individuals affected by neurodevelopmental disorders.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n22\nYet, modifications of early development might present higher inter-tissue concordance (Heijmans and Mill, 2012). The brain may be the most suitable source for the identification of disease biomarkers (Bakulski et al., 2016), but its analysis can be problematic and highly impractical due to limited availability of post-mortem data, the impossibility to infer causality, and degeneration of the genetic material (Wen et al., 2016). In addition, as epigenetic marks can change across the lifetime (Bell and Spector, 2011), modifications measured after patients’ death may not be representative of the ones present during disorder onset or course. Peripheral blood is easier to access and can be collected at any age, it enables analysis of larger samples and can be examined longitudinally (Bakulski et al., 2016). Interestingly, Smith et al. (2015) suggested saliva as a more appropriate peripheral tissue than blood, due to its greater similarity to brain tissue. Importantly, since we are unaware of whether neurodevelopmental disorders depend on DNA methylation variations in the brain only or in multiple tissues, we suggest the analysis of different tissue types. When this approach is not feasible, consulting online resources showing correlations between peripheral tissues and brain is advised. Moreover, focusing on the use and development of non-invasive techniques for in vivo brain analysis, such as brain imaging, is of importance (Rakyan et al., 2011).\nEpigenetic patterns not only vary across tissues, but also within tissues as these contain a mixture\nof cell types such as leucocytes and red blood cells in whole blood or neurons and glial cells in brain. Failure to account for such heterogeneity can severely confound results. For instance, if cases and controls diverge in their cell-type proportions, observed epigenetic differences might reflect cell-type composition rather than the phenotype of interest (Bock, 2012; Rakyan et al., 2011). The methods commonly employed to address cellular heterogeneity include cell sorting, reference-based (e.g. Houseman’s constrained projection) and reference-free methods (e.g. RefFreeEWAS). Cell sorting provides the exact proportion of different cell types in a specific sample but is more costly and labor-intensive than the alternatives. Reference-based and reference-free methods, estimating cell-type composition with algorithms (Teschendorff and Zheng, 2017), provide a more feasible yet less accurate option. Of the reviewed studies, AC CE\nPT ED\nM AN\nUS CR\nIP T\n23\nonly a minority corrected for cell-type heterogeneity. Most publications used reference-based methods, a few studies selected histologically identical cells, purified cells or reference-free methods, and two employed cell sorting (Nardone et al., 2017; Wong et al., 2014). Given the importance of accounting for cellular heterogeneity, Birney et al. (2016) suggested analyzing purified or histologically identical cells together with using any mean available to quantify cell-type proportions.\nIn the reviewed studies, epigenetic findings tended to be solely based on statistical significance. It\nis however unclear to what extent statistically significant CpGs/regions reflect a functional effect (i.e. variation in the phenotype). In order to solve this issue, Barker et al. (2017) proposed the integration of DNA methylation data with other omics (e.g. proteomics), the use of animal models and of in vitro experiments. Several studies conducted gene expression or gene set enrichment analyses and could thus bridge the gap between statistical and functional significance (e.g. Aldinger et al., 2013; Ginsberg et al., 2012).\nThe limited understanding of the role of epigenetics in mental health disorders constitutes another\nkey challenge in this field. Epigenetic modifications could exert a causal role in disorder etiology by mediating or modifying genetic or environmental risk or by representing the biological mechanism for gene-environment interactions (Ladd-Acosta and Fallin, 2016). Conversely, if not pathways to disorder onset, epigenetic alterations could be biomarkers of exposure to environmental factors or to the disorder itself. If epigenetics mediates the relation between environment and disorder, scientists might be able to help reverse psychiatric conditions by altering nutrition, behavior, social factors, and with the use of drugs (Rutten and Mill, 2009). On the other hand, improvements in the accuracy of diagnoses and of illness detection could be achieved in case epigenetic modifications are biomarkers of disease (Ladd-Acosta and Fallin, 2016). Characterizing the role of epigenetics with respect to disorder, environment, and genotype would greatly contribute to moving the field forward, enabling appropriate interpretation of epigenetic findings and informing potential translational applications for public health. AC CE PT ED\nM AN\nUS CR\nIP T\n24\nIn conclusion, current evidence suggests the possibility of an association between epigenetic\nmodifications and neurodevelopmental disorders. Yet, with very few exceptions, the results were either conflicting or not independently replicated. The available research is limited and hampered by small samples, suboptimal designs and heterogeneity in approaches, analyses and tissues. While scientists are still far from understanding the causal, diagnostic or prognostic role of epigenetics in neurodevelopmental disorders, this field is exciting due to its rapid development and advances. Longitudinal and geneticallysensitive designs, increased samples sizes, adjustments for appropriate confounders and integration of omics-data will permit the delineation of the role of this promising field in ASD and ADHD. Careful investigations of epigenetic processes in relation to these and other neurodevelopmental disorders are highly recommended.\nFUNDING: This work was supported by Metagenics Inc.\nDECLARATION OF INTEREST: TM and OHF work in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc. and AXA. TM reported receiving research support from Metagenics.Inc. JN has been financially supported by Erasmus Mundus Western Balkans (ERAWEB), a project funded by the European Commission. OHF reported receiving grants or research support from Metagenics Inc. The work of HT was supported by grants from the EU Seventh Framework Program (FP7/2007-2013, Action, grant number 602768) and the Netherlands Organization for Scientific Research (NWO-grant 016.VICI.170.200). CC is supported by the Economic and Social Research Council (grant ref: ES/N001273/1). These funding sources had no role in designing and conducting the study; in collection, management, analysis, and interpretation of the data; in writing, reviewing or approving the manuscript for publication. AC CE\nPT ED\nM AN\nUS CR\nIP T\nREFERENCES\n[dataset] Geer, L., Marchler-Bauer, A., Geer, R., Han, L., He, J., He, S., Liu, C., Shi, W., Bryant, S., 2010. The NCBI BioSystems database. Nucleid Acids Res, D492-496. http://dx.doi.org/10.1093/nar/gkp858. [dataset] Shuman, C., Beckwith, J.B., Weksberg, R., 2016. Beckwith-Wiedemann Syndrome. GeneReviews. [dataset] Smith, C.L., Blake, J.A., Kadin, J.A., Richardson, J.E., Bult, C.J., Mouse Genome Database, G., 2018. Mouse Genome Database (MGD)-2018: knowledgebase for the laboratory mouse. Nucleic Acids Res 46, D836-D842. http://dx.doi.org/10.1093/nar/gkx1006. [dataset] Weizmann Institute of Science, c2018. PathCards: Signaling by GPCR Pathway in Signaling by GPCR SuperPath Weizmann Institute of Science. Adriani, W., Romano, E., Pucci, M., Pascale, E., Cerniglia, L., Cimino, S., Tambelli, R., Curatolo, P., Granstrem, O., Maccarrone, M., Laviola, G., D'Addario, C., 2017. Potential for diagnosis versus therapy monitoring of attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype and auto-immunity. European child & adolescent psychiatry. Aldinger, K.A., Plummer, J.T., Levitt, P., 2013. Comparative DNA methylation among females with neurodevelopmental disorders and seizures identifies TAC1 as a MeCP2 target gene. J Neurodev Disord 5, 15. American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders, fifth ed., Arlington, VA. Atsem, S., Reichenbach, J., Potabattula, R., Dittrich, M., Nava, C., Depienne, C., Bohm, L., Rost, S., Hahn, T., Schorsch, M., Haaf, T., El Hajj, N., 2016. Paternal age effects on sperm FOXK1 and KCNA7 methylation and transmission into the next generation. Human Mol Genet 25, 4996-5005. Bakulski, K.M., Halladay, A., Hu, V.W., Mill, J., Fallin, M.D., 2016. Epigenetic Research in Neuropsychiatric Disorders: the \"Tissue Issue\". Curr Behav Neurosci Rep 3, 264-274. Bannister, A.J., Kouzarides, T., 2011. Regulation of chromatin by histone modifications. Cell Res 21, 381-395. Barker, E.D., Walton, E., Cecil, C.A.M., 2017. Annual Research Review: DNA methylation as a mediator in the association between risk exposure and child and adolescent psychopathology. J Child Psychol Psychiatry. Bell, J.T., Spector, T.D., 2011. A twin approach to unraveling epigenetics. Trends Genet 27, 116-125. Bennetto, L., Kuschner, E.S., Hyman, S.L., 2007. Olfaction and taste processing in autism. Biol Psychiatry 62, 1015-1021. Berko, E.R., Suzuki, M., Beren, F., Lemetre, C., Alaimo, C.M., Calder, R.B., Ballaban-Gil, K., Gounder, B., Kampf, K., Kirschen, J., Maqbool, S.B., Momin, Z., Reynolds, D.M., Russo, N., Shulman, L., Stasiek, E., Tozour, J., Valicenti-McDermott, M., Wang, S., Abrahams, B.S., Hargitai, J., Inbar, D., Zhang, Z., Buxbaum, J.D., Molholm, S., Foxe, J.J., Marion, R.W., Auton, A., Greally, J.M., 2014. Mosaic Epigenetic Dysregulation of Ectodermal Cells in Autism Spectrum Disorder. PLoS Genet 10. Betancur, C., 2011. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 1380, 42-77. Birney, E., Smith, G.D., Greally, J.M., 2016. Epigenome-wide Association Studies and the Interpretation of Disease -Omics. PLoS Genet 12, e1006105. Bock, C., 2012. Analysing and interpreting DNA methylation data. Nat Rev Genet 13, 705-719. Bonora, E., Bacchelli, E., Levy, E.R., Blasi, F., Marlow, A., Monaco, A.P., Maestrini, E., 2002. Mutation screening and imprinting analysis of four candidate genes for autism in the 7q32 region. Mol Psychiatry 7, 289-301. Booth, M.J., Branco, M.R., Ficz, G., Oxley, D., Krueger, F., Reik, W., Balasubramanian, S., 2012. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 336, 934-937. AC CE PT ED M AN US CR IP T\n26\nBoyle, C.A., Boulet, S., Schieve, L.A., Cohen, R.A., Blumberg, S.J., Yeargin-Allsopp, M., Visser, S., Kogan, M.D., 2011. Trends in the prevalence of developmental disabilities in US children, 1997-2008. Pediatrics 127, 1034-1042. Braun, K.V., Voortman, T., Dhana, K., Troup, J., Bramer, W.M., Troup, J., Chowdhury, R., Dehghan, A., Muka, T., Franco, O.H., 2016. The role of DNA methylation in dyslipidaemia: A systematic review. Prog Lipid Res 64, 178-191. Cecil, C.A., Walton, E., Viding, E., 2015. DNA methylation, substance use and addiction: a systematic review of recent animal and human research from a developmental perspective. Curr Addict Rep 2, 331- 346. Delgado, M.S., Camprubí, C., Tümer, Z., Martínez, F., Milà, M., Monk, D., 2014. Screening individuals with intellectual disability, autism and Tourette's syndrome for KCNK9 mutations and aberrant DNA methylation within the 8q24 imprinted cluster. Am J Med Genet Part B Neuropsychiatr Genet 165, 472- 478. Elia, J., Sackett, J., Turner, T., Schardt, M., Tang, S.C., Kurtz, N., Dunfey, M., McFarlane, N.A., Susi, A., Danish, D., Li, A., Nissley-Tsiopinis, J., Borgmann-Winter, K., 2012. Attention-deficit/hyperactivity disorder genomics: update for clinicians. Curr Psychiatry Rep 14, 579-589. Faraone, S.V., Perlis, R.H., Doyle, A.E., Smoller, J.W., Goralnick, J.J., Holmgren, M.A., Sklar, P., 2005. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57, 1313-1323. Feil, R., Fraga, M.F., 2012. Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 13, 97-109. Feinberg, J.I., Bakulski, K.M., Jaffe, A.E., Tryggvadottir, R., Brown, S.C., Goldman, L.R., Croen, L.A., Hertz-Picciotto, I., Newschaffer, C.J., Daniele Fallin, M., Feinberg, A.P., 2015. Paternal sperm DNA methylation associated with early signs of autism risk in an autism-enriched cohort. Int J Epidemiol 44, 1199-1210. Fullard, J.F., Halene, T.B., Giambartolomei, C., Haroutunian, V., Akbarian, S., Roussos, P., 2016. Understanding the genetic liability to schizophrenia through the neuroepigenome. Schizophr Res 177, 115-124. Gaunt, T.R., Shihab, H.A., Hemani, G., Min, J.L., Woodward, G., Lyttleton, O., Zheng, J., Duggirala, A., McArdle, W.L., Ho, K., Ring, S.M., Evans, D.M., Davey Smith, G., Relton, C.L., 2016. Systematic identification of genetic influences on methylation across the human life course. Genome Biol 17, 61. Ginsberg, M.R., Rubin, R.A., Falcone, T., Ting, A.H., Natowicz, M.R., 2012. Brain Transcriptional and Epigenetic Associations with Autism. PLoS ONE 7. Heijmans, B.T., Mill, J., 2012. Commentary: The seven plagues of epigenetic epidemiology. Int J Epidemiol 41, 74-78. Hill, P.W., Amouroux, R., Hajkova, P., 2014. DNA demethylation, Tet proteins and 5- hydroxymethylcytosine in epigenetic reprogramming: an emerging complex story. Genomics 104, 324- 333. Hilton, C.L., Harper, J.D., Kueker, R.H., Lang, A.R., Abbacchi, A.M., Todorov, A., LaVesser, P.D., 2010. Sensory responsiveness as a predictor of social severity in children with high functioning autism spectrum disorders. J Autism Dev Disord 40, 937-945. Homberg, J.R., Kyzar, E.J., Nguyen, M., Norton, W.H., Pittman, J., Poudel, M.K., Gaikwad, S., Nakamura, S., Koshiba, M., Yamanouchi, H., Scattoni, M.L., Ullman, J.F., Diamond, D.M., Kaluyeva, A.A., Parker, M.O., Klimenko, V.M., Apryatin, S.A., Brown, R.E., Song, C., Gainetdinov, R.R., Gottesman, II, Kalueff, A.V., 2016. Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models. Neurosci Biobehav Rev 65, 292-312. Homs, A., Codina-Sola, M., Rodriguez-Santiago, B., Villanueva, C.M., Monk, D., Cusco, I., PerezJurado, L.A., 2016. Genetic and epigenetic methylation defects and implication of the ERMN gene in autism spectrum disorders. Transl Psychiatry 6, e855. Hranilovic, D., Blazevic, S., Stefulj, J., Zill, P., 2016. DNA Methylation Analysis of HTR2A Regulatory Region in Leukocytes of Autistic Subjects. Autism Res 9, 204-209. AC CE PT ED M AN US CR IP T\n27\nHuang, Y., Pastor, W.A., Shen, Y., Tahiliani, M., Liu, D.R., Rao, A., 2010. The behaviour of 5- hydroxymethylcytosine in bisulfite sequencing. PLoS One 5, e8888. James, S.J., Shpyleva, S., Melnyk, S., Pavliv, O., Pogribny, I.P., 2013. Complex epigenetic regulation of Engrailed-2 (EN-2) homeobox gene in the autism cerebellum. Transl Psychiatry 3, e232. Jiang, Y., Sahoo, T., Shinawi, M., Michaelis, R.C., Buyse, I., Kashork, C.D., Schroer, R.J., Roa, B.B., Stockton, D.W., Spielman, R.S., Stevenson, R.E., Shaffer, L.G., Beaudet, A.L., 2004. A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A. Am. J. Hum. Genet. 131A, 1-10. Keil, K.P., Lein, P.J., 2016. DNA methylation: a mechanism linking environmental chemical exposures to risk of autism spectrum disorders? Environ Epigenet 2, 1-15. Kilpinen, H., Dermitzakis, E.T., 2012. Genetic and epigenetic contribution to complex traits. Hum Mol Genet 21, R24-28. Kouzarides, T., 2007. Chromatin modifications and their function. Cell 128, 693-705. Kubota, T., Mochizuki, K., 2016. Epigenetic Effect of Environmental Factors on Autism Spectrum Disorders. Int J Environ Res Public Health 13. Ladd-Acosta, C., Fallin, M.D., 2016. The role of epigenetics in genetic and environmental epidemiology. Epigenomics 8, 271-283. Ladd-Acosta, C., Hansen, K.D., Briem, E., Fallin, M.D., Kaufmann, W.E., Feinberg, A.P., 2014. Common DNA methylation alterations in multiple brain regions in autism. Mol Psychiatry 19, 862-871. LaSalle, J.M., 2013. Epigenomic strategies at the interface of genetic and environmental risk factors for autism. J Hum Genet 58, 396-401. Latham, K.E., Sapienza, C., Engel, N., 2012. The epigenetic lorax: gene-environment interactions in human health. Epigenomics 4, 383-402. Leyfer, O.T., Folstein, S.E., Bacalman, S., Davis, N.O., Dinh, E., Morgan, J., Tager-Flusberg, H., Lainhart, J.E., 2006. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 36, 849-861. Lichtenstein, P., Carlstrom, E., Rastam, M., Gillberg, C., Anckarsater, H., 2010. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 167, 1357-1363. Lintas, C., Sacco, R., Persico, A.M., 2016. Differential methylation at the RELN gene promoter in temporal cortex from autistic and typically developing post-pubertal subjects. J Neurodevelopmental Disord 8, 18. Loke, Y.J., Hannan, A.J., Craig, J.M., 2015. The Role of Epigenetic Change in Autism Spectrum Disorders. Front Neurol 6, 107. Mill, J., Heijmans, B.T., 2013. From promises to practical strategies in epigenetic epidemiology. Nat Rev Genet 14, 585-594. Mitchell, M.M., Woods, R., Chi, L.H., Schmidt, R.J., Pessah, I.N., Kostyniak, P.J., Lasalle, J.M., 2012. Levels of select PCB and PBDE congeners in human postmortem brain reveal possible environmental involvement in 15q11-q13 duplication autism spectrum disorder. Environ Mol Mutagen 53, 589-598. Moore, L.D., Le, T., Fan, G., 2013. DNA methylation and its basic function. Neuropsychopharmacology 38, 23-38. Muka, T., Koromani, F., Portilla, E., O'Connor, A., Bramer, W.M., Troup, J., Chowdhury, R., Dehghan, A., Franco, O.H., 2016a. The role of epigenetic modifications in cardiovascular disease: A systematic review. Int J Cardiol 212, 174-183. Muka, T., Nano, J., Voortman, T., Braun, K.V.E., Ligthart, S., Stranges, S., Bramer, W.M., Troup, J., Chowdhury, R., Dehghan, A., Franco, O.H., 2016b. The role of global and regional DNA methylation and histone modifications in glycemic traits and type 2 diabetes: A systematic review. Nutr Metab Cardiovasc Dis 26, 553-566. Nagarajan, R.P., Hogart, A.R., Gwye, Y., Martin, M.R., LaSalle, J.M., 2006. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics 1, e1-11. AC CE PT ED M AN US CR IP T\n28\nNagarajan, R.P., Patzel, K.A., Martin, M., Yasui, D.H., Swanberg, S.E., Hertz-Picciotto, I., Hansen, R.L., Van de Water, J., Pessah, I.N., Jiang, R., Robinson, W.P., LaSalle, J.M., 2008. MECP2 promoter methylation and X chromosome inactivation in autism. Autism Res 1, 169-178. Nardone, S., Sams, D.S., Zito, A., Reuveni, E., Elliott, E., 2017. Dysregulation of Cortical Neuron DNA Methylation Profile in Autism Spectrum Disorder. Cereb Cortex, 1-16. Nardone, S., Sharan Sams, D., Reuveni, E., Getselter, D., Oron, O., Karpuj, M., Elliott, E., 2014. DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways. Transl Psychiatry 4, e433. Nguyen, A.T., Rauch, T.A., Pfeifer, G.P., Hu, V.W., 2010. … cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. The FASEB Journal. Non, A.L., Thayer, Z.M., 2015. Epigenetics for anthropologists: An introduction to methods. Am J Hum Biol 27, 295-303. Philibert, R.A., Sandhu, H., Hollenbeck, N., Gunter, T., Adams, W., Madan, A., 2008. The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am J Med Genet B Neuropsychiatr Genet 147B, 543-549. Polanczyk, G.V., Willcutt, E.G., Salum, G.A., Kieling, C., Rohde, L.A., 2014. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43, 434-442. Rakyan, V.K., Down, T.A., Balding, D.J., Beck, S., 2011. Epigenome-wide association studies for common human diseases. Nat Rev Genet 12, 529-541. Rutten, B.P., Mill, J., 2009. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull 35, 1045-1056. Scholz, C.J., Jacob, C.P., Buttenschon, H.N., Kittel-Schneider, S., Boreatti-Hummer, A., Zimmer, M., Walter, U., Lesch, K.P., Mors, O., Kneitz, S., Deckert, J., Reif, A., 2010. Functional variants of TSPAN8 are associated with bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 153B, 967-972. Schroeder, D.I., Schmidt, R.J., Crary-Dooley, F.K., Walker, C.K., Ozonoff, S., Tancredi, D.J., HertzPicciotto, I., LaSalle, J.M., 2016. Placental methylome analysis from a prospective autism study. Mol Autism 7, 51. Schuch, V., Utsumi, D.A., Costa, T.V., Kulikowski, L.D., Muszkat, M., 2015. Attention Deficit Hyperactivity Disorder in the Light of the Epigenetic Paradigm. Front Psychiatry 6, 126. Smith, A.K., Kilaru, V., Klengel, T., Mercer, K.B., Bradley, B., Conneely, K.N., Ressler, K.J., Binder, E.B., 2015. DNA extracted from saliva for methylation studies of psychiatric traits: evidence tissue specificity and relatedness to brain. Am J Med Genet B Neuropsychiatr Genet 168B, 36-44. Sun, W., Poschmann, J., Cruz-Herrera del Rosario, R., Parikshak, N.N., Hajan, H.S., Kumar, V., Ramasamy, R., Belgard, T.G., Elanggovan, B., Wong, C.C.Y., Mill, J., Geschwind, D.H., Prabhakar, S., 2016. Histone Acetylome-wide Association Study of Autism Spectrum Disorder. Cell 167, 1385. Szulwach, K.E., Li, X., Li, Y., Song, C.X., Wu, H., Dai, Q., Irier, H., Upadhyay, A.K., Gearing, M., Levey, A.I., Vasanthakumar, A., Godley, L.A., Chang, Q., Cheng, X., He, C., Jin, P., 2011. 5-hmCmediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 14, 1607- 1616. Taurines, R., Schwenck, C., Westerwald, E., Sachse, M., Siniatchkin, M., Freitag, C., 2012. ADHD and autism: differential diagnosis or overlapping traits? A selective review. Atten Defic Hyperact Disord 4, 115-139. Teschendorff, A.E., Zheng, S.C., 2017. Cell-type deconvolution in epigenome-wide association studies: a review and recommendations. Epigenomics 9, 757-768. Tordjman, S., Somogyi, E., Coulon, N., Kermarrec, S., Cohen, D., Bronsard, G., Bonnot, O., WeismannArcache, C., Botbol, M., Lauth, B., Ginchat, V., Roubertoux, P., Barburoth, M., Kovess, V., Geoffray, AC C PT ED M AN US CR IP T\n29\nM.M., Xavier, J., 2014. Gene x Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Front Psychiatry 5, 53. Tsai, P.C., Bell, J.T., 2015. Power and sample size estimation for epigenome-wide association scans to detect differential DNA methylation. Int J Epidemiol. Tsang, S.Y., Ahmad, T., Mat, F.W., Zhao, C., Xiao, S., Xia, K., Xue, H., 2016. Variation of global DNA methylation levels with age and in autistic children. Hum Genomics 10, 31. van Bokhoven, H., 2011. Genetic and epigenetic networks in intellectual disabilities. Annu Rev Genet 45, 81-104. Van Mil, N.H., Steegers-Theunissen, R.P.M., Bouwland-Both, M.I., Verbiest, M.M.P.J., Rijlaarsdam, J., Hofman, A., Steegers, E.A.P., Heijmans, B.T., Jaddoe, V.W.V., Verhulst, F.C., Stolk, L., Eilers, P.H.C., Uitterlinden, A.G., Tiemeier, H., 2014. DNA methylation profiles at birth and child ADHD symptoms. J Psychiatr Res 49, 51-59. Visser, J.C., Rommelse, N.N., Greven, C.U., Buitelaar, J.K., 2016. Autism spectrum disorder and attention-deficit/hyperactivity disorder in early childhood: A review of unique and shared characteristics and developmental antecedents. Neurosci Biobehav Rev 65, 229-263. Walton, E., Pingault, J.B., Cecil, C.A., Gaunt, T.R., Relton, C.L., Mill, J., Barker, E.D., 2017. Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study. Mol Psychiatry 22, 250- 256. Wang, Y., Fang, Y., Zhang, F., Xu, M., Zhang, J., Yan, J., Ju, W., Brown, W.T., Zhong, N., 2014. Hypermethylation of the enolase gene (ENO2) in autism. Eur J Pediatr 173, 1233-1244. Wei, W., Pelechano, V., Jarvelin, A.I., Steinmetz, L.M., 2011. Functional consequences of bidirectional promoters. Trends Genet 27, 267-276. Weksberg, R., 2010. Imprinted genes and human disease. Am J Med Genet C Semin Med Genet 154C, 317-320. Wen, K.X., Milic, J., El-Khodor, B., Dhana, K., Nano, J., Pulido, T., Kraja, B., Zaciragic, A., Bramer, W.M., Troup, J., Chowdhury, R., Ikram, M.A., Dehghan, A., Muka, T., Franco, O.H., 2016. The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review. PLoS One 11, e0167201. Wilmot, B., Fry, R., Smeester, L., Musser, E.D., Mill, J., Nigg, J.T., 2016. Methylomic analysis of salivary DNA in childhood ADHD identifies altered DNA methylation in VIPR2. J Child Psychol Psychiatry 57, 152-160. Wong, C.C.Y., Meaburn, E.L., Ronald, A., Price, T.S., Jeffries, A.R., Schalkwyk, L.C., Plomin, R., Mill, J., 2014. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. Mol Psychiatry 19, 495-503. Xu, Y., Chen, X.T., Luo, M., Tang, Y., Zhang, G., Wu, D., Yang, B., Ruan, D.Y., Wang, H.L., 2015. Multiple epigenetic factors predict the attention deficit/hyperactivity disorder among the Chinese Han children. J Psychiatr Res 64, 40-50. Zhu, X., Higashimoto, K., Soejima, H., Yatsuki, H., Sugihara, H., Mukai, T., Joh, K., 2000. C11orf21, a novel gene within the Beckwith-Wiedemann syndrome region in human chromosome 11p15.5. Gene 256, 311-317.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\nFigure captions:\nFigure 1. PRISMA flow diagram of the studies included in this systematic review. Of the 2174 retrieved articles, after deduplication, we screened the title and/or abstract of 2169 publications and identified 86 potentially relevant ones. Based on a full-text assessment of their eligibility, 29 publications were included in this systematic review. Abbreviations: n=number.\nAC CE\nPT ED\nM AN\nUS CR\nIP\nT\nRecords identified through database\nsearching\n(n = 2164)\nSc re\nen in g In cl u d ed El ig ib ili ty\nId\nen ti\nfi ca\nti o\nn\nAdditional records identified\nthrough other sources\n(n = 10)\nRecords after duplicates removed\n(n = 2169)\nRecords screened\n(n = 2169)\nRecords excluded\n(n = 2083)\nFull-text articles assessed\nfor eligibility\n(n = 86)\nFull-text articles excluded,\nwith reasons\n(n = 57)\n17 No control group 3 full text not found\n6 not examining DNA methylation or histone\nmodifications\n5 not examining ASD or\nADHD in particular\n26 not empirical studies\nStudies included in\nqualitative synthesis\n(n = 29)\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n32\nTable 1. Global DNA methylation and Autism Spectrum Disorder.\nAuthor Cases\n/Controls\nSample Characteristics\nTissue Adjustments/Matching Method Findings Significance\nLevel\nBrain tissue James et al. (2013)\n13/13 from 2 samples\nUSA 4-30 y. M and F\nCB Matched by age, sex, race, PMI and cause\nof death.\nLC-MS/MS Hypermethylation (5.9±1.2 in ASD\npatients, 4.7±1.1 in controls).\np < 0.05\nMitchell et al. (2012)\n12/12 USA 4-61 y.\nM and F\nBA19 Sex, birth period, brain region /age and sex. LINE-1 No significant differences. p < 0.05\nPeripheral tissue Schroeder et al. (2016) 24/23\nUSA Birth to 36m. M and F\nPlacenta, CBL and nonspecified\nSex, sequencing run number, order of sequencing, average sequencing coverage / sex and birth year. MethylCsequencing\nNo significant differences. FDR < 0.05\nTsang et al. (2016)\n280/236\nChina MASD = 4.7 y. Mcontrols=5.3 y. M and F\nLeukocytes Matched by age. HpaII/MspI Hypermethylation (∆β = 54.35±21.37) in autistic subjects.\np < 0.05\nWong et al. (2014)\n66/44\nUK Birth to 15y. sex NA\nWB Adjusted for blood cell count. LUMA No significant differences (M =\n65.1% in autistic twin, M = 65.9% in unaffected twin).\np < 0.82 (based on observed p-value)\nASD = Autism Spectrum Disorder; BA Brodmann’s Area; CB = cerebellum; CBL = cord blood; F = females; FDR = false discovery rate; M = males; m. = months; NA = not available; PMI = postmortem interval; WB = whole blood; y. = years. AC CE\nPT ED\nM AN\nUS CR\nIP T\n33\nTable 2. Epigenome-wide DNA methylation and Autism Spectrum Disorder.\nAuthor Cases\n/Controls\nSample Characteristics Tissue Statistical Analysis\nPlatform Replication\nValidation\nAdjustments /Matching\nFindings Significance\nLevel\nBrain tissue Feinberg et al. (2015) 19/21\nNA FC, TC, CB DMR Infinium\n450k array\nNone None Differential DNA methylation in\nSNORD family genes in CB, in 12 regions in FC and 10 regions in TC.\np < 0.05\nGinsberg et al. (2012)\n17/17 from 2 samples USA, UK, Canada\nand unknown 1-60 y. M\nBA19 and cerebellar hemispheric cortex. DMP Infinium 27k array\nNone Region and age /\nage and sex.\nNo significant differences.\nFDR ≤ 0.05 and FDR ≤ 0.25\nLaddAcosta et al. (2014) 20/21 from 3 samples USA NA\nTC, PFC, CB DMR Infinium\n450k array\nReplication, 25/26 Sex, cell type / age,\nsex and PMI\nDNA hypomethylation in cases in PRRT1 (∆M = -7.8%.), C11orf21/TSPAN32 (∆M = - 6.6%) and DNA hypermethylation in ZFP57 (∆M = 13.9%) in cases in TC. DNA hypermethylation in SDHAP3 in cases in cerebellum (∆M = 15.8%). Differential DNA methylation replicated in the same regions encompassing PRRT1 and C11orf21/TSPAN32. NB: Replication analyses were conducted in a different brain tissue of the same individuals in DMR: FWER ≤ 0.1 Replication: p < 0.05 AC CE\nPT ED\nM AN\nUS CR\nIP T\n34\nAuthor Cases\n/Controls\nSample Characteristics Tissue Statistical Analysis\nPlatform Replication\nValidation\nAdjustments /Matching\nFindings Significance\nLevel\nthe discovery cohort.\nNardone et al. (2017)\n15/16 from 2 samples UK, USA 17-68 y.\nM\nPFC, BA10, BA9, BA8 DMR DMP\nInfinium 450k array Validation with NGBS\nTechnical and biological covariates / age, brain mass and PMI\nNo significant differential DNA methylation in DMP analysis. Differential DNA methylation in 58 regions, spanning GABBR1, ABAT, Mir124-1, Mir124-2 in DMR analysis DNA hypomethylation in GABBR1 and Mir124-2 and DNA hypermethylation in FAM124B and InNEAT1 in cases validated. Pathways: synaptic and neuronal processes and immune response processes. DMP and DMR: FDR < 0.05 Validation: p < 0.05\nNardone et al. (2014)\n24/23 from 2 samples UK, USA\n16-51 y. M and F\nBA10, BA24 DMP Infinium\n450k array\nValidation with pyrosequencing\nAdjusted for sex and batch effects\nDifferential DNA methylation in 5329 CpGs in BA10 and 10745 in BA24, including HDAC4, PRRT1, C11orf21/TSPAN32, C1qA, IRF8, CTSZ. DNA hypomethylation of C11orf21 (∆β = 0.39 to -4.93) and C1qA (∆β = -3.45), IRF8 (∆β = -3.42), CTSZ (∆β = -2.13 to - 3.39) in BA10 in cases validated. Pathways: immune responses, neuron-neuron synaptic transmission. DMP: FDR < 0.05 Validation: p < 0.06 (based on observed pvalues)\nPeripheral tissue\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n35\nAuthor Cases\n/Controls\nSample Characteristics Tissue Statistical Analysis\nPlatform Replication\nValidation\nAdjustments /Matching\nFindings Significance\nLevel\nAldinger et al. (2013)\n4/6\nUSA Age NA F\nLCL DMP and\ngrouping of CpG sites\nInfinium 27k array\nReplication in 13/13. Validation with MassArray EpiTYPER.\nMatched by age Differential methylation in 261\nprobes (|∆β| > 0.15), including probes in PTCD2, TAC1, HOXA11, TCN1, ETNK2. Results not replicated. Differential DNA methylation in PTCD2, FLJ44881, SPAG7, TAC1 in the pooled analysis. TAC1 validated. .\nDMP: p < 0.01, FDR < 0.10 Replication and pooled: p < 0.0005 Validation: p < 0.005\nBerko et al. (2014) 47/48\nUSA 1-28 y. M and F\nBuccal tissue DMR Infinium\n450k array\nValidation with NGBS\nAdjustment for sex, age, ancestry, SNPs, technical variables, ASD status, microarraybased variables and batch effects Differential DNA methylation in 13 genes: OR2L13(β = -8.0%), PAX8 (β = -7.5%), GPC1 (β = - 8.6%), ADRA2C (β = -11.9%), FAM134B (β = -7.8%), CREB5 (β = 7.6%), NOS1 (β = 8.6%), MAPK8IP3 (β = 9%), HOOK2 (β\n= -7.9%), NRG2 (β = 7.6%), KCNQ5 (β = 7.7%), ZG16B (β = 10.1%), LOC643802 (β = -8.9%). OR2L13 validated as hypomethylated.\nDMP:1-log10 (based on observed values for FAM134B, ORL13) or unclear (for other genes). Validation: p < 0.05\nHoms et al. (2016) 53/757 from 4\nsamples\nSpain, USA and other Europeans Age 2-101 M and F\nPB, CBL, WB\nDMP, DMR and individual analysis (each single case compared to 10 controls) Infinium 450k array Replication in 415/405. Validation with Sanger BS and pyrosequencing.\nMatched by age in one sample.\nNo significant differences in DMP analysis. Differential DNA methylation in DMR analysis in five regions in four patients only. Differential DNA methylation in 700 CpGs in the individual analysis due to rare genetic variants. Differential DNA methylation in individual analysis replicated in DMP: q ≤ 0.01. DMR: p < 0.01 Individual analysis:p < 0.01, f < 0.005\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n36\nAuthor Cases\n/Controls\nSample Characteristics Tissue Statistical Analysis\nPlatform Replication\nValidation\nAdjustments /Matching\nFindings Significance\nLevel\n17/700 CpGs. Differential DNA methylation in DMR validated. Pathways: AMP-activated protein kinase signaling.\nNguyen et al. (2010) 5/9\nUSA 2-19y M\nLCL DMP MIRA Validation with\nMSP or Sanger BS\nNone Differential DNA methylation in\n73 CpG islands between discordant monozygotic twins. Differential DNA methylation in 201 CpG islands when comparing both twins to unaffected siblings. DNA hypermethylation in BCL-2 (M = ~25% in ASD, M = 9.5% in controls) and RORA in cases. Results were validated. Pathways: inflammation and apoptosis, brain morphogenesis, cellular differentiation, growth rate, myelination, cytokine production, synaptic regulation, steroid biosynthesis, learning.\nDMP: log2 - 0.938 (based on observed values) Validation: not reported.\nSchroeder et al. (2016) 24/23\nUSA Birth to 36m. M and F\nPlacenta Grouping of\nCpG sites\nWGBS Validation with\npyrosequencing\nSequencing run, order, coverage, child ethnicity, sex / sex and birthyear. DNA hypermethylation near DLL1 and LOC15444 in cases. Results were validated.\nGrouping of CpG sites: FDR ≤ 0.05 Validation: p < 0.05.\nWang et al. (2014) 5/5\nChina 3-12y. M and F\nVenous B DMR\n(promoters and CpG islands)\nMeDIP Replication,\n131/131 Validation with Sanger BS\nMatched by age and sex.\nDifferential DNA methylation in 228 gene promoters and 247 CpG islands when comparing 5 cases and 5 controls. DNA hypermethylation in ENO2 promoter replicated in 15% of the replication sample (M = 39.1% in autistic patients, M = 18.81% in controls). DMR: p < 0.05 Replication: p < 0.01 Validation: p < 0.01\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n37\nAuthor Cases\n/Controls\nSample Characteristics Tissue Statistical Analysis\nPlatform Replication\nValidation\nAdjustments /Matching\nFindings Significance\nLevel\nWong et al. (2014) 66/44\nUK Birth to 15y. M and F\nWB DMP (one for\ndiscordant twins, one for cases vs. controls)\nInfinium 27k array\nValidation with pyrosequencing\nAdjusted for cell count.\nDNA hypomethylation in the promoter of PIK3C3 in affected twins (∆β = -0.04) in DMR. DNA hypomethylation in NFYC in affected twin in DMP analysis. Differential DNA methylation in MGC3207(∆β = -0.24), OR2L13(∆β = 0.18) and C14orf152(∆β = -0.16) between cases and controls. OR2L13 (r = 0.86) and MGC3207 (r = 0.91) validated. DMP (twins): p < 0.018 (based on observed pvalues for top 50 hits) DMP (casescontrols): p < 0.00062 (based on observed pvalues for top 50 hits)\nValidation: not reported.\nASD = Autism Spectrum Disorder; B = blood; BA = Brodmann’s Area; CB = cerebellum; CBL = cord blood; DMP = differentially methylated positions; DMR = differentially methylated regions; F = females; FC = frontal cortex; FDR = false discovery rate; FWER = familywise error rate; LCL = lymphoblastoid cell lines; M = males; NA = not available; PB = peripheral blood; PFC = prefrontal cortex; PMI = post-mortem interval; = TC = temporal cortex; WB = whole blood; WGCNA = weighted gene co-expression network analysis; y. = years.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n38\nTable 3. Candidate gene DNA methylation and Autism Spectrum Disorder.\nAuthor Cases\n/Controls\nSample Characteristics\nTissue Gene Statistical\nAnalysis\nPlatform Adjustments\n/Matching\nFindings Significance\nLevel\nBrain tissue Ginsberg et al. (2012) >7/>7\nUSA, UK, Canada and unknown 1-60 y. M\nBA19 and cerebellar hemispheric cortex.\nRORA, BCL2, UBE3A, MECP2, OXTR, CEBPD DMP Pyrosequencing Matched by age and sex.\nNo significant differences. FWER ≤ 0.05\nJames et al. (2013) 13/13 from 2\nsamples\nUSA 4-30 y. M and F\nCB EN-2 (promoter) DMP Restriction\nenzymes\nMatched by age, sex, PMI, cause of death and race. DNA hypermethylation in autistic patients in all restriction enzymes used (McrBC-PCR analysis:23±4% of DNA methylation in ASD, 10±2% of\nDNA methylation in controls); (MSRPCR :38±7% in ASD, 15±5% in controls).\np < 0.05\nJiang et al. (2004) 17/60 from 3\nsamples\nNA\nCB, CC SNRPN 5’-end,\nUBE3A (3’and 5’-end)\nDMR Restriction\nenzymes\nNone Differential DNA methylation in one\nparticipant in UBE3A. NB: This was the only candidate gene DNA methylation study performing validation (Sanger BS).\nNot reported\nLintas et al. (2016) 6/6 from 3 samples USA 16-30 y.\n10M and 2F\nBA41/42, BA22\nRELN (promoter)\nDMR Sanger BS Matched by age,\nsex and PMI.\nDifferential DNA methylation distribution. Hypermethylation in the 5’ portion in autistic subjects (29.55±13.09 in cases, 5.70±2.90 in controls).\np < 0.05\nMitchell et al. (2012) 12/12\nUSA 4-61 y. M and F\nBA19 OCA2\n(promoter)\nDMP Pyrosequencing Sex, birth period,\nbrain region/ age and sex\nNo significant differences.\np < 0.05\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n39\nAuthor Cases\n/Controls\nSample Characteristics\nTissue Gene Statistical\nAnalysis\nPlatform Adjustments\n/Matching\nFindings Significance\nLevel\nNagarajan et al. (2008)\n9/9 from 4 samples USA\n2-21 y. M and F\nBA9 MECP2\n(promoter region II)\nDMR Sanger BS Matched by age,\nsex and geographical area.\nNo significant differences.\np < 0.07 (based on observed pvalue)\nNagarajan et al. (2006)\n20/27 from 4 samples\nUSA 76days – 57 y. 32M\nBA9, FG MECP2\n(promoter region I)\nDMR Sanger BS None DNA hypermethylation in autistic\nsubjects. NB: Site 3 of region I is the only site of MeCP2 showing a statistically significant higher DNA methylation in cases than controls.\np < 0.05.\nPeripheral tissue Atsem et al. (2016) 74/41 from 3\nsamples\nFrance, Germany 2-20y. M B FOXK1 DMR NGBS Age/age and sex No significant differences.\nNot reported.\nBonora et al. (2002)\n46/10\nConsortium NA\nL PEG1/MEST,\nCOPG2 (CpG islands)\nDMR Restriction\nenzymes\nNone No significant differences. Not reported.\nDelgado et al. (2014) 86/48\nSpain Age and sex NA\nPB PEG13, KCNK9,\nTRAPPC9\nDMR Pyrosequencing None No significant differences. Not reported\nHranilovic et al. (2016) 90/66\nCroatia 4-60 y. M and F\nL HTR2A\n(promoter)\nDMR Sanger BS Age, sex and\ngenotype/ age and genotype\nDNA hypermethylation in the AG subgroup of autistic patients. No significant differences for the AA and GG subgroups. Adjusted p ≤ 0.05\nASD = Autism Spectrum Disorder; B = blood; BA = Brodmann’s Area; CB = cerebellum; CC = cerebral cortex; DMP = differentially methylated positions; DMR = differentially methylated regions; F = females; FG = fusiform gyrus; FWER = familywise error rate; L = leucocytes; M = males; NA = not available; NB = nota bene; PB = peripheral blood; PMI = post-mortem interval; RBC = red blood cells; y. = years.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\n40\nTable 4. Histone modifications and Autism Spectrum Disorder.\nAuthor Cases/Controls Sample\nCharacteristics\nTissue Histone and\nLysine\nAdjustments/Matching Findings Significance\nLevel\nJames et al. (2013) 11/11\nUSA 4-30y. M and F\nCB H3K27\nH3K4\nMatched by age, sex, race, cause of death and PMI.\nH3K27 trimethylation levels decreased in ASD individuals. No significant trymethylation differences in H3K4.\np < 0.05\nSun et al. (2016)\n45/49\nConsortium 10-81 y. M and F\nPFC, TC, CB\nH3K27 Adjusted for sex, age, proportion of neurons, multiple technical covariates.\nDifferential acetylation in cortices and cerebellum.\nq ≤ 0.05\nASD = Autism Spectrum Disorder; CB = cerebellum; F = females; H = histone; K = lysine; M = males; PFC = prefrontal cortex; PMI = post-mortem interval; TC = temporal cortex; y. = years.\nAC CE\nPT ED\nM AN\nUS CR\nIP T\nUS\nCR\nIP T\nUS\nCR\nIP T"
    } ],
    "references" : [ {
      "title" : "Bryant",
      "author" : [ "L. Geer", "A. Marchler-Bauer", "R. Geer", "L. Han", "J. He", "S. He", "C. Liu", "W. Shi" ],
      "venue" : "S.,",
      "citeRegEx" : "dataset",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Weksberg",
      "author" : [ "C. Shuman", "J.B. Beckwith" ],
      "venue" : "R.,",
      "citeRegEx" : "dataset",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Potential for diagnosis versus therapy",
      "author" : [ "O. Granstrem", "M. Maccarrone", "G. Laviola", "C. D'Addario" ],
      "venue" : null,
      "citeRegEx" : "Granstrem et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Granstrem et al\\.",
      "year" : 2017
    }, {
      "title" : "Comparative DNA methylation among females",
      "author" : [ "K.A. Aldinger", "J.T. Plummer", "P. Levitt" ],
      "venue" : null,
      "citeRegEx" : "Aldinger et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Aldinger et al\\.",
      "year" : 2013
    }, {
      "title" : "Paternal age effects on sperm FOXK1 and KCNA7",
      "author" : [ "T. Hahn", "M. Schorsch", "T. Haaf", "N. El Hajj" ],
      "venue" : null,
      "citeRegEx" : "Hahn et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Hahn et al\\.",
      "year" : 2016
    }, {
      "title" : "Epigenetic Research",
      "author" : [ "K.M. Bakulski", "A. Halladay", "V.W. Hu", "J. Mill", "M.D. Fallin" ],
      "venue" : null,
      "citeRegEx" : "Bakulski et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Bakulski et al\\.",
      "year" : 2016
    }, {
      "title" : "Regulation of chromatin by histone modifications",
      "author" : [ "A.J. Bannister", "T. Kouzarides" ],
      "venue" : "Cell Res",
      "citeRegEx" : "Bannister and Kouzarides,? \\Q2011\\E",
      "shortCiteRegEx" : "Bannister and Kouzarides",
      "year" : 2011
    }, {
      "title" : "Annual Research Review: DNA methylation as a mediator",
      "author" : [ "E.D. Barker", "E. Walton", "C.A.M. Cecil" ],
      "venue" : null,
      "citeRegEx" : "Barker et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Barker et al\\.",
      "year" : 2017
    }, {
      "title" : "A twin approach to unraveling epigenetics",
      "author" : [ "J.T. Bell", "T.D. Spector" ],
      "venue" : "Trends Genet",
      "citeRegEx" : "Bell and Spector,? \\Q2011\\E",
      "shortCiteRegEx" : "Bell and Spector",
      "year" : 2011
    }, {
      "title" : "Olfaction and taste processing in autism",
      "author" : [ "L. Bennetto", "E.S. Kuschner", "S.L. Hyman" ],
      "venue" : null,
      "citeRegEx" : "Bennetto et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Bennetto et al\\.",
      "year" : 2007
    }, {
      "title" : "Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and",
      "author" : [ "C. Betancur" ],
      "venue" : null,
      "citeRegEx" : "Betancur,? \\Q2011\\E",
      "shortCiteRegEx" : "Betancur",
      "year" : 2011
    }, {
      "title" : "Epigenome-wide Association Studies and the Interpretation",
      "author" : [ "E. Birney", "G.D. Smith", "J.M. Greally" ],
      "venue" : null,
      "citeRegEx" : "Birney et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Birney et al\\.",
      "year" : 2016
    }, {
      "title" : "Analysing and interpreting DNA methylation data",
      "author" : [ "C. Bock" ],
      "venue" : "Nat Rev Genet",
      "citeRegEx" : "Bock,? \\Q2012\\E",
      "shortCiteRegEx" : "Bock",
      "year" : 2012
    }, {
      "title" : "Trends in the prevalence of developmental disabilities in US children, 1997-2008",
      "author" : [ "C.A. Boyle", "S. Boulet", "L.A. Schieve", "R.A. Cohen", "S.J. Blumberg", "M. Yeargin-Allsopp", "S. Visser", "M.D. Kogan" ],
      "venue" : null,
      "citeRegEx" : "Boyle et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Boyle et al\\.",
      "year" : 2011
    }, {
      "title" : "DNA methylation, substance use and addiction: a systematic review of recent animal and human research from a developmental perspective",
      "author" : [ "C.A. Cecil", "E. Walton", "E. Viding" ],
      "venue" : "Lipid Res",
      "citeRegEx" : "Cecil et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Cecil et al\\.",
      "year" : 2015
    }, {
      "title" : "disability, autism and Tourette's syndrome for KCNK9 mutations and aberrant DNA methylation within the 8q24 imprinted cluster",
      "author" : [ "J. Sackett", "T. Turner", "M. Schardt", "S.C. Tang", "N. Kurtz", "M. Dunfey", "N.A. McFarlane", "A. Susi", "D. Danish", "A. Li", "J. Nissley-Tsiopinis", "K. Borgmann-Winter" ],
      "venue" : "Am J Med Genet Part B Neuropsychiatr Genet",
      "citeRegEx" : "J. et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "J. et al\\.",
      "year" : 2012
    }, {
      "title" : "disorder genomics: update for clinicians",
      "author" : [ "S.V. Faraone", "R.H. Perlis", "A.E. Doyle", "J.W. Smoller", "J.J. Goralnick", "M.A. Holmgren", "P. Sklar" ],
      "venue" : "Curr Psychiatry Rep 14,",
      "citeRegEx" : "Faraone et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "Faraone et al\\.",
      "year" : 2005
    }, {
      "title" : "Paternal sperm DNA methylation associated with early signs of autism risk in an autism-enriched cohort",
      "author" : [ "J.I. Feinberg", "K.M. Bakulski", "A.E. Jaffe", "R. Tryggvadottir", "S.C. Brown", "L.R. Goldman", "L.A. Croen", "I. Hertz-Picciotto", "C.J. Newschaffer", "M. Daniele Fallin", "A.P. Feinberg" ],
      "venue" : "Int J Epidemiol",
      "citeRegEx" : "Feinberg et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Feinberg et al\\.",
      "year" : 2015
    }, {
      "title" : "Understanding the genetic liability to schizophrenia through the neuroepigenome",
      "author" : [ "T.R. Gaunt", "H.A. Shihab", "G. Hemani", "J.L. Min", "G. Woodward", "O. Lyttleton", "J. Zheng", "A. Duggirala", "W.L. McArdle", "K. Ho", "S.M. Ring", "D.M. Evans", "G. Davey Smith", "C.L. Relton" ],
      "venue" : "Schizophr Res",
      "citeRegEx" : "Gaunt et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Gaunt et al\\.",
      "year" : 2016
    }, {
      "title" : "Brain Transcriptional and Epigenetic Associations with Autism",
      "author" : [ "M.R. Ginsberg", "R.A. Rubin", "T. Falcone", "A.H. Ting", "M.R. Natowicz" ],
      "venue" : "PLoS ONE 7",
      "citeRegEx" : "Ginsberg et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Ginsberg et al\\.",
      "year" : 2012
    }, {
      "title" : "hydroxymethylcytosine in epigenetic reprogramming: an emerging complex story",
      "author" : [ "C.L. Hilton", "J.D. Harper", "R.H. Kueker", "A.R. Lang", "A.M. Abbacchi", "A. Todorov", "P.D. LaVesser" ],
      "venue" : "J Autism Dev Disord",
      "citeRegEx" : "Hilton et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Hilton et al\\.",
      "year" : 2010
    }, {
      "title" : "Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models",
      "author" : [ "J.R. Homberg", "E.J. Kyzar", "M. Nguyen", "W.H. Norton", "J. Pittman", "M.K. Poudel", "S. Gaikwad", "S. Nakamura", "M. Koshiba", "H. Yamanouchi", "M.L. Scattoni", "J.F. Ullman", "D.M. Diamond", "A.A. Kaluyeva", "M.O. Parker", "V.M. Klimenko", "S.A. Apryatin", "R.E. Brown", "C. Song", "R.R. Gainetdinov", "II Gottesman", "A.V. Kalueff" ],
      "venue" : "Neurosci Biobehav Rev",
      "citeRegEx" : "Homberg et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Homberg et al\\.",
      "year" : 2016
    }, {
      "title" : "Genetic and epigenetic methylation defects and implication of the ERMN gene in autism spectrum disorders",
      "author" : [ "A. Homs", "M. Codina-Sola", "B. Rodriguez-Santiago", "C.M. Villanueva", "D. Monk", "I. Cusco", "L.A. PerezJurado" ],
      "venue" : "Transl Psychiatry",
      "citeRegEx" : "Homs et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Homs et al\\.",
      "year" : 2016
    }, {
      "title" : "The behaviour of 5hydroxymethylcytosine in bisulfite sequencing",
      "author" : [ "Y. Huang", "W.A. Pastor", "Y. Shen", "M. Tahiliani", "D.R. Liu", "A. Rao" ],
      "venue" : "PLoS One",
      "citeRegEx" : "Huang et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2010
    }, {
      "title" : "A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A",
      "author" : [ "D.W. Stockton", "R.S. Spielman", "R.E. Stevenson", "L.G. Shaffer", "A.L. Beaudet" ],
      "venue" : "Am. J. Hum. Genet. 131A,",
      "citeRegEx" : "Stockton et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Stockton et al\\.",
      "year" : 2004
    }, {
      "title" : "Genetic and epigenetic contribution to complex traits",
      "author" : [ "H. Kilpinen", "E.T. Dermitzakis" ],
      "venue" : "Hum Mol Genet",
      "citeRegEx" : "Kilpinen and Dermitzakis,? \\Q2012\\E",
      "shortCiteRegEx" : "Kilpinen and Dermitzakis",
      "year" : 2012
    }, {
      "title" : "The role of epigenetics in genetic and environmental epidemiology",
      "author" : [ "C. Ladd-Acosta", "M.D. Fallin" ],
      "venue" : "Epigenomics 8,",
      "citeRegEx" : "Ladd.Acosta et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ladd.Acosta et al\\.",
      "year" : 2014
    }, {
      "title" : "The epigenetic lorax: gene-environment interactions in human health",
      "author" : [ "K.E. Latham", "C. Sapienza", "N. Engel" ],
      "venue" : "autism. J Hum Genet",
      "citeRegEx" : "Latham et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Latham et al\\.",
      "year" : 2012
    }, {
      "title" : "The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood",
      "author" : [ "P. Lichtenstein", "E. Carlstrom", "M. Rastam", "C. Gillberg", "H. Anckarsater" ],
      "venue" : "rates of disorders. J Autism Dev Disord",
      "citeRegEx" : "Lichtenstein et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Lichtenstein et al\\.",
      "year" : 2010
    }, {
      "title" : "The Role of Epigenetic Change in Autism Spectrum Disorders",
      "author" : [ "Y.J. 18. Loke", "A.J. Hannan", "J.M. Craig" ],
      "venue" : "Disord",
      "citeRegEx" : "Loke et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Loke et al\\.",
      "year" : 2015
    }, {
      "title" : "Levels of select PCB and PBDE congeners in human postmortem brain reveal possible environmental involvement in 15q11-q13 duplication autism spectrum disorder",
      "author" : [ "M.M. Mitchell", "R. Woods", "L.H. Chi", "R.J. Schmidt", "I.N. Pessah", "P.J. Kostyniak", "J.M. Lasalle" ],
      "venue" : "Environ Mol Mutagen",
      "citeRegEx" : "Mitchell et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Mitchell et al\\.",
      "year" : 2012
    }, {
      "title" : "The role of epigenetic modifications in cardiovascular disease: A systematic review",
      "author" : [ "T. Muka", "F. Koromani", "E. Portilla", "A. O'Connor", "W.M. Bramer", "J. Troup", "R. Chowdhury", "A. Dehghan", "O.H. Franco" ],
      "venue" : "Int J Cardiol",
      "citeRegEx" : "Muka et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Muka et al\\.",
      "year" : 2016
    }, {
      "title" : "histone modifications in glycemic traits and type 2 diabetes: A systematic review",
      "author" : [ "R.P. Nagarajan", "A.R. Hogart", "Y. Gwye", "M.R. Martin", "J.M. LaSalle" ],
      "venue" : "Nutr Metab Cardiovasc Dis 26,",
      "citeRegEx" : "Nagarajan et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Nagarajan et al\\.",
      "year" : 2006
    }, {
      "title" : "MECP2 promoter methylation and X chromosome inactivation in autism",
      "author" : [ "R.P. Nagarajan", "K.A. Patzel", "M. Martin", "D.H. Yasui", "S.E. Swanberg", "I. Hertz-Picciotto", "R.L. Hansen", "J. Van de Water", "I.N. Pessah", "R. Jiang", "W.P. Robinson", "J.M. LaSalle" ],
      "venue" : "Autism Res",
      "citeRegEx" : "Nagarajan et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Nagarajan et al\\.",
      "year" : 2008
    }, {
      "title" : "DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways",
      "author" : [ "S. Nardone", "D. Sharan Sams", "E. Reuveni", "D. Getselter", "O. Oron", "M. Karpuj", "E. Elliott" ],
      "venue" : "Transl Psychiatry",
      "citeRegEx" : "Nardone et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Nardone et al\\.",
      "year" : 2014
    }, {
      "title" : "Epigenetics for anthropologists: An introduction to methods",
      "author" : [ "R.A. Philibert", "H. Sandhu", "N. Hollenbeck", "T. Gunter", "W. Adams", "A. Madan" ],
      "venue" : "autistic brain. The FASEB Journal. Non,",
      "citeRegEx" : "Philibert et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Philibert et al\\.",
      "year" : 2015
    }, {
      "title" : "alcohol dependence in subjects from the Iowa Adoption Studies",
      "author" : [ "G.V. Polanczyk", "E.G. Willcutt", "G.A. Salum", "C. Kieling", "L.A. Rohde" ],
      "venue" : "Am J Med Genet B Neuropsychiatr Genet 147B,",
      "citeRegEx" : "Polanczyk et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Polanczyk et al\\.",
      "year" : 2014
    }, {
      "title" : "Epigenome-wide association studies for common human diseases",
      "author" : [ "V.K. Rakyan", "T.A. Down", "D.J. Balding", "S. Beck" ],
      "venue" : "Nat Rev Genet 12,",
      "citeRegEx" : "Rakyan et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Rakyan et al\\.",
      "year" : 2011
    }, {
      "title" : "Functional variants of TSPAN8 are associated with bipolar disorder and schizophrenia",
      "author" : [ "U. Walter", "K.P. Lesch", "O. Mors", "S. Kneitz", "J. Deckert", "A. Reif" ],
      "venue" : "Am J Med Genet B Neuropsychiatr Genet 153B,",
      "citeRegEx" : "Walter et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Walter et al\\.",
      "year" : 2010
    }, {
      "title" : "Attention Deficit Hyperactivity Disorder in the Light of the Epigenetic Paradigm",
      "author" : [ "V. Schuch", "D.A. Utsumi", "T.V. Costa", "L.D. Kulikowski", "M. Muszkat" ],
      "venue" : "Autism",
      "citeRegEx" : "Schuch et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Schuch et al\\.",
      "year" : 2015
    }, {
      "title" : "specificity and relatedness to brain",
      "author" : [ "J. Poschmann", "R. Cruz-Herrera del Rosario", "N.N. Parikshak", "H.S. Hajan", "V. Kumar", "R. Ramasamy", "T.G. Belgard", "B. Elanggovan", "C.C.Y. Wong", "J. Mill", "D.H. Geschwind", "S. Prabhakar" ],
      "venue" : "Am J Med Genet B Neuropsychiatr Genet",
      "citeRegEx" : "W. et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "W. et al\\.",
      "year" : 2016
    }, {
      "title" : "5-hmCmediated epigenetic dynamics during postnatal neurodevelopment and aging",
      "author" : [ "A.I. Levey", "A. Vasanthakumar", "L.A. Godley", "Q. Chang", "X. Cheng", "C. He", "P. Jin" ],
      "venue" : "Nat Neurosci 14,",
      "citeRegEx" : "Levey et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Levey et al\\.",
      "year" : 2011
    }, {
      "title" : "Cell-type deconvolution in epigenome-wide association studies: a review and recommendations",
      "author" : [ "A.E. Teschendorff", "S.C. Zheng" ],
      "venue" : "Epigenomics 9,",
      "citeRegEx" : "Teschendorff and Zheng,? \\Q2017\\E",
      "shortCiteRegEx" : "Teschendorff and Zheng",
      "year" : 2017
    }, {
      "title" : "Gene x Environment interactions in autism spectrum disorders: role of epigenetic mechanisms",
      "author" : [ "M.M", "J. Xavier" ],
      "venue" : "Front Psychiatry",
      "citeRegEx" : "M.M. and Xavier,? \\Q2014\\E",
      "shortCiteRegEx" : "M.M. and Xavier",
      "year" : 2014
    }, {
      "title" : "methylation levels with age and in autistic children",
      "author" : [ "H. van Bokhoven" ],
      "venue" : "Hum Genomics 10,",
      "citeRegEx" : "Bokhoven,? \\Q2011\\E",
      "shortCiteRegEx" : "Bokhoven",
      "year" : 2011
    }, {
      "title" : "DNA methylation profiles at birth and child ADHD symptoms",
      "author" : [ "A.G. Uitterlinden", "H. Tiemeier" ],
      "venue" : "J Psychiatr Res",
      "citeRegEx" : "Uitterlinden and Tiemeier,? \\Q2014\\E",
      "shortCiteRegEx" : "Uitterlinden and Tiemeier",
      "year" : 2014
    }, {
      "title" : "Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study",
      "author" : [ "E. Walton", "J.B. Pingault", "C.A. Cecil", "T.R. Gaunt", "C.L. Relton", "J. Mill", "E.D. Barker" ],
      "venue" : "Mol Psychiatry",
      "citeRegEx" : "Walton et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Walton et al\\.",
      "year" : 2017
    }, {
      "title" : "Functional consequences of bidirectional promoters",
      "author" : [ "W. Wei", "V. Pelechano", "A.I. Jarvelin", "L.M. Steinmetz" ],
      "venue" : "Trends Genet",
      "citeRegEx" : "Wei et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Wei et al\\.",
      "year" : 2011
    }, {
      "title" : "The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review",
      "author" : [ "W.M", "J. Troup", "R. Chowdhury", "M.A. Ikram", "A. Dehghan", "T. Muka", "O.H. Franco" ],
      "venue" : "PLoS One 11,",
      "citeRegEx" : "W.M. et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "W.M. et al\\.",
      "year" : 2016
    }, {
      "title" : "Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits",
      "author" : [ "C.C.Y. Wong", "E.L. Meaburn", "A. Ronald", "T.S. Price", "A.R. Jeffries", "L.C. Schalkwyk", "R. Plomin", "J. Mill" ],
      "venue" : "Mol Psychiatry",
      "citeRegEx" : "Wong et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Wong et al\\.",
      "year" : 2014
    }, {
      "title" : "Multiple epigenetic factors predict the attention deficit/hyperactivity disorder among the Chinese Han children",
      "author" : [ "K. Higashimoto", "H. Soejima", "H. Yatsuki", "H. Sugihara", "T. Mukai", "K. Joh" ],
      "venue" : "J Psychiatr Res",
      "citeRegEx" : "X. et al\\.,? \\Q2000\\E",
      "shortCiteRegEx" : "X. et al\\.",
      "year" : 2000
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Brain Tissue: Associations in MeCP2 – a gene coding for a protein with a methyl-CpG binding domain ([dataset] Geer et al.",
      "startOffset" : 100,
      "endOffset" : 109
    }, {
      "referenceID" : 0,
      "context" : "(2016) found higher DNA methylation in autistic subjects of mixed age in a region of HTR2A – a gene encoding a receptor for serotonin ([dataset] Geer et al.",
      "startOffset" : 135,
      "endOffset" : 144
    }, {
      "referenceID" : 0,
      "context" : "A similar role in normal/neurological phenotypes was described for the mice homolog prrt1, which is also implicated in central nervous system functioning ([dataset] Smith et al.",
      "startOffset" : 155,
      "endOffset" : 164
    }, {
      "referenceID" : 0,
      "context" : "Beckwith-Wiedemann syndrome ([dataset] Geer et al.",
      "startOffset" : 29,
      "endOffset" : 38
    }, {
      "referenceID" : 0,
      "context" : ", 2010), a disease characterized by genetic and epigenetic dysregulation ([dataset] Shuman et al.",
      "startOffset" : 74,
      "endOffset" : 83
    }, {
      "referenceID" : 0,
      "context" : "autism among individuals suffering from Beckwith-Wiedemann syndrome ([dataset] Shuman et al.",
      "startOffset" : 69,
      "endOffset" : 78
    }, {
      "referenceID" : 0,
      "context" : "Mice studies have also observed involvement in olfactory receptor activity in the homologs of OR2L13, olfr166 and olfr168 ([dataset] Smith et al.",
      "startOffset" : 123,
      "endOffset" : 132
    }, {
      "referenceID" : 0,
      "context" : "Vipr2 was also found to be involved in hypo-activity in mice models ([dataset] Smith et al.",
      "startOffset" : 69,
      "endOffset" : 78
    }, {
      "referenceID" : 0,
      "context" : "Interestingly, both VIPR2 (for ADHD) and OR2LI3 (for ASD) are involved in the signaling by G-protein-coupled-receptors (GPCR) pathway ([dataset] Weizmann Institute of Science, c2018), which includes genes responsive to stimuli external to the cell, including odors and neurotransmitters.",
      "startOffset" : 135,
      "endOffset" : 144
    } ],
    "year" : 2018,
    "abstractText" : "Epigenetic processes have been suggested as key mechanisms in the etiology of neurodevelopmental disorders. This systematic review summarizes the current evidence for an association between epigenetics and Autism Spectrum Disorder (ASD) and Attention/Deficit-Hyperactivity Disorder (ADHD). Six databases were searched until the 24 of October 2017. Of the 2169 retrieved articles, 29 met our inclusion criteria. While generally associations between epigenetics and neurodevelopmental disorders were reported, only a few findings were consistent across independent analyses. Differential epigenetic markers were repeatedly identified in OR2L13, C11orf21/TSPAN32, PRRT1 and H3K27 for autism, and in VIPR2 for ADHD. Overall, evidence of an association between epigenetic modifications and ASD or ADHD should be considered preliminary and based on studies suffering from numerous caveats. We highlight the need for carefully designed investigations and for greater homogeneity and provide specific recommendations for future research. Despite our current limited understanding, the suggestive findings and the rapid advances in the field hold the promise of a forthcoming elucidation of the role of epigenetic modifications in neurodevelopmental disorders.",
    "creator" : "Elsevier"
  }
}